JP2013532576A - 薬剤送達のための注入用装置および方法 - Google Patents
薬剤送達のための注入用装置および方法 Download PDFInfo
- Publication number
- JP2013532576A JP2013532576A JP2013523370A JP2013523370A JP2013532576A JP 2013532576 A JP2013532576 A JP 2013532576A JP 2013523370 A JP2013523370 A JP 2013523370A JP 2013523370 A JP2013523370 A JP 2013523370A JP 2013532576 A JP2013532576 A JP 2013532576A
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- needle
- treatment
- chamber
- treatment fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 238000001802 infusion Methods 0.000 title claims description 120
- 238000012377 drug delivery Methods 0.000 title description 16
- 238000011282 treatment Methods 0.000 claims abstract description 688
- 239000012530 fluid Substances 0.000 claims abstract description 639
- 239000003814 drug Substances 0.000 claims abstract description 447
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 419
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 106
- 239000007924 injection Substances 0.000 claims description 137
- 238000002347 injection Methods 0.000 claims description 137
- 239000000203 mixture Substances 0.000 claims description 111
- 238000009472 formulation Methods 0.000 claims description 109
- 238000000926 separation method Methods 0.000 claims description 101
- 230000036961 partial effect Effects 0.000 claims description 83
- 210000004127 vitreous body Anatomy 0.000 claims description 77
- 239000007788 liquid Substances 0.000 claims description 75
- 210000003786 sclera Anatomy 0.000 claims description 61
- 210000000795 conjunctiva Anatomy 0.000 claims description 58
- 230000004888 barrier function Effects 0.000 claims description 55
- 230000000007 visual effect Effects 0.000 claims description 55
- 230000000149 penetrating effect Effects 0.000 claims description 54
- 239000011148 porous material Substances 0.000 claims description 34
- 230000007246 mechanism Effects 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 230000001886 ciliary effect Effects 0.000 claims description 15
- 230000008878 coupling Effects 0.000 claims description 13
- 238000010168 coupling process Methods 0.000 claims description 13
- 238000005859 coupling reaction Methods 0.000 claims description 13
- 230000009977 dual effect Effects 0.000 claims description 12
- 239000003381 stabilizer Substances 0.000 claims description 12
- 238000002513 implantation Methods 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 9
- 210000003128 head Anatomy 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 7
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000035515 penetration Effects 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 description 164
- 108091006146 Channels Proteins 0.000 description 146
- 239000000463 material Substances 0.000 description 89
- 239000000243 solution Substances 0.000 description 53
- 230000000875 corresponding effect Effects 0.000 description 47
- 239000011230 binding agent Substances 0.000 description 39
- 238000013268 sustained release Methods 0.000 description 38
- 239000012730 sustained-release form Substances 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 37
- 239000002245 particle Substances 0.000 description 32
- -1 polytetrafluoroethylene Polymers 0.000 description 32
- 239000012528 membrane Substances 0.000 description 27
- 238000005192 partition Methods 0.000 description 26
- 210000001525 retina Anatomy 0.000 description 25
- 229940076783 lucentis Drugs 0.000 description 22
- 230000014759 maintenance of location Effects 0.000 description 22
- 229910052751 metal Inorganic materials 0.000 description 22
- 239000002184 metal Substances 0.000 description 22
- 150000003384 small molecules Chemical class 0.000 description 21
- 239000004480 active ingredient Substances 0.000 description 19
- 238000009792 diffusion process Methods 0.000 description 19
- 229940120638 avastin Drugs 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 238000010586 diagram Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000003204 osmotic effect Effects 0.000 description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 229960003876 ranibizumab Drugs 0.000 description 10
- 229940126585 therapeutic drug Drugs 0.000 description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 9
- 239000000017 hydrogel Substances 0.000 description 9
- 239000007943 implant Substances 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000006798 recombination Effects 0.000 description 9
- 229940074410 trehalose Drugs 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 239000000560 biocompatible material Substances 0.000 description 8
- 230000001295 genetical effect Effects 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 239000002090 nanochannel Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 229960002930 sirolimus Drugs 0.000 description 8
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 239000000919 ceramic Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 7
- 239000013583 drug formulation Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229960000397 bevacizumab Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000004240 ciliary body Anatomy 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 230000005484 gravity Effects 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000002086 nanomaterial Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 5
- 229960002117 triamcinolone acetonide Drugs 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 4
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 4
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 4
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 4
- 239000004696 Poly ether ether ketone Substances 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 102000003923 Protein Kinase C Human genes 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
- 210000001217 buttock Anatomy 0.000 description 4
- 210000003161 choroid Anatomy 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000013013 elastic material Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 229960002143 fluorescein Drugs 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960003407 pegaptanib Drugs 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 229920002530 polyetherether ketone Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229940068977 polysorbate 20 Drugs 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 229960000371 rofecoxib Drugs 0.000 description 4
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 239000012780 transparent material Substances 0.000 description 4
- 229960005294 triamcinolone Drugs 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 3
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 3
- 102000000521 Immunophilins Human genes 0.000 description 3
- 108010016648 Immunophilins Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100022337 Integrin alpha-V Human genes 0.000 description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 108010048673 Vitronectin Receptors Proteins 0.000 description 3
- 150000003869 acetamides Chemical class 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 229940043075 fluocinolone Drugs 0.000 description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000005373 porous glass Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 210000001585 trabecular meshwork Anatomy 0.000 description 3
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- ZCJNAMSVGLRGEL-UHFFFAOYSA-N 1-methylsulfonyl-4-(1-phenylethenyl)benzene Chemical compound CS(=O)(=O)C1=CC=C(C=C1)C(=C)C1=CC=CC=C1 ZCJNAMSVGLRGEL-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 2
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 108010082340 Arginine deiminase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102400000730 Canstatin Human genes 0.000 description 2
- 101800000626 Canstatin Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102400001047 Endostatin Human genes 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 108091011114 FK506 binding proteins Proteins 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102000012355 Integrin beta1 Human genes 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- 102000008607 Integrin beta3 Human genes 0.000 description 2
- 108010020950 Integrin beta3 Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 2
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012990 dithiocarbamate Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229960000936 fumagillin Drugs 0.000 description 2
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229940092110 macugen Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229950001248 squalamine Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 229940099039 velcade Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- AQOKCDNYWBIDND-ABRBVVEGSA-N 5-trans-17-phenyl trinor Prostaglandin F2alpha ethyl amide Chemical compound CCNC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-ABRBVVEGSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010058207 Anistreplase Proteins 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 1
- 0 CCCC1(C)CC2=*(C)CCC2CC1 Chemical compound CCCC1(C)CC2=*(C)CCC2CC1 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 229910001200 Ferrotitanium Inorganic materials 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004962 Polyamide-imide Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 108010047196 Urofollitropin Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- JPKKQJKQTPNWTR-BRYCGAMXSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1 JPKKQJKQTPNWTR-BRYCGAMXSA-N 0.000 description 1
- DPHFJXVKASDMBW-RQRKFSSASA-N [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O DPHFJXVKASDMBW-RQRKFSSASA-N 0.000 description 1
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940003677 alphagan Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229960000983 anistreplase Drugs 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003431 anti-prostaglandin Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 229940098085 betagan Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940094657 botulinum toxin type a Drugs 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- WMEMLXDTLKSUOD-OGCOPIPOSA-N chembl436844 Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@@H](CC=2C3=CC=CC=C3N(C)C=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](C)C(=O)N1)C(C)C)=O)NC(=O)[C@@H](NC(C)=O)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 WMEMLXDTLKSUOD-OGCOPIPOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940105756 coagulation factor x Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960004120 defibrotide Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229950002420 eucatropine Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960002907 follitropin beta Drugs 0.000 description 1
- 108010081934 follitropin beta Proteins 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960005390 galsulfase Drugs 0.000 description 1
- 108010089296 galsulfase Proteins 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 229910000856 hastalloy Inorganic materials 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229950005360 hydroxyamfetamine Drugs 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 108010072166 idursulfase Proteins 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 229940028862 interferon gamma-1b Drugs 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010000594 mecasermin Proteins 0.000 description 1
- 229960001311 mecasermin Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960001002 nepafenac Drugs 0.000 description 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 108010027841 pegademase bovine Proteins 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960002995 pegvisomant Drugs 0.000 description 1
- 108700037519 pegvisomant Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005596 polymer binder Polymers 0.000 description 1
- 239000002491 polymer binding agent Substances 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 description 1
- 229960002758 sermorelin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000012781 shape memory material Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000007725 thermal activation Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960004371 urofollitropin Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- JLQFVGYYVXALAG-CFEVTAHFSA-N yasmin 28 Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 JLQFVGYYVXALAG-CFEVTAHFSA-N 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/027—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body having a particular valve, seal or septum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0276—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for introducing or removing fluids into or out of the body
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
本国際特許出願は、2010年8月5日に出願された米国特許出願第61/371154号、名称「薬剤送達のための注入用装置および方法」(代理人整理番号93161−790300(004400US));2011年6月20日に出願された米国特許出願第61/499,095号、名称「薬剤送達のための注入用装置および方法」(代理人整理番号93161−809222(004410US));2011年6月24日に出願された米国特許出願第61/501,021号、名称「薬剤送達のための注入用装置および方法」(代理人整理番号93161−810847(004420US));2011年7月1日に出願された米国特許出願第61/504,038号、名称「薬剤送達のための注入用装置および方法」(代理人整理番号93161−813922(004430US));2010年8月5日に出願された第61/371169号、名称「埋め込み型治療デバイス」、(代理人整理番号93161−790659(004600US));2011年6月9日に出願された米国特許出願第61/495,251号、名称「診断方法および装置」(代理人整理番号93161−808320(000100US));および2011年6月10日に出願された米国特許出願第61/495,718号、名称「診断方法および装置」(代理人整理番号93161−808370(00011OUS))に基づく優先権を主張し、その全開示を参照によりここに援用するものである。
該当無し
(a)免疫グロブリンG 150キロダルトン 10.5nm
(b)ウシ血清アルブミン 69キロダルトン 7.2nm
(c)免疫グロブリンGのFabフラグメント 49キロダルトン 流体力学的直径の報告なし
放出速度=(DP/F)A(cR−cV)/L
但し、
cR=リザーバ内の濃度
cV=リザーバ外、すなわち硝子体内の濃度
D=リザーバ溶液中の治療薬の拡散係数
P=多孔質構造体の多孔率
F=多孔質構造体のチャネルの蛇行パラメータに対応し得るチャネル・パラメータ
A=多孔質構造体の面積
L=多孔質構造体の厚さ(長さ)
累積放出率=1−cR/cR0=1−exp((−DPA/FLVR)t)
但し、t=時間、Vr=リザーバ容積
DTA,37C=DBSA,20C=(η20C/η37C)(MWBSA/MWTA)1/3
但し、MWは、BSAまたはテスト化合物の分子量を表し、ηは水の粘度である。以下に、対象となるタンパク質の拡散係数の一覧を示す。
cR=cR0exp((−D PA/FL VR)t)
累積放出=1−cR/cR0
cV=デバイスからの放出速度/kVV
速度=Vr(dCr/dt)=−D(PA/TL)Cr
但し、速度=デバイスからの治療薬放出速度
Cr=リザーバ中の治療薬濃度
Vr=リザーバ容積
D=拡散定数
PA/TL=RRI
P=多孔率
A=面積
T=蛇行率=F=チャネル・パラメータ
実質的に一定の容積での注入の場合
Cr0=(注入容積)(製剤濃度)/Vr
但し、Cr0=製剤の注入後のリザーバ中の初期濃度
注入容積=50μLの場合
Cr0=(0.05mL)(10mg/mL)/Vr(1000μg/1mg)=500μg/Vr
速度=x(500μg)exp(−xt)
但し、t=時間
x=(D/Vr)(PA/TL)
硝子体での質量バランスを考慮して
Vv(dCv/dt)=デバイスからの速度=kVvCv
但し、Vv=硝子体容積(約4.5mL)
Cv=硝子体中の治療薬濃度
k=硝子体からの薬の速度(硝子体中の薬の半減期の逆数に比例)
ここに記載される実施態様に適切な場合、すなわちCvが実質的に一定のままであり時間とともにゆっくりと変化する(すなわち、dCv/dtが約0)場合、
Cv=(デバイスからの速度)/(kVv)
kVvが実質的に一定であるので、Cvの最大値は、デバイスからの速度を最大にする条件に対応するであろう。デバイスへの注入後任意の時間(例えば180日)に、最大速度を与えるxの値で最大Cv値が得られる。xの最適値は、任意の時間で、
d(速度)/dx=0を満たす。
速度=500(x)exp(−xt)=f(x)g(x)
但し、f(x)=500x,g(x)=exp(−xt)
d(速度)/dx=f’(x)g(x)+f(x)g’(x)=500(1−xt)exp(−xt)
任意の時間tに対して,1−xt=0すなわちxt=1のとき、d(速度)/dx=0となる。
速度は、(D/Vr)(PA/TL)t=1のとき最大となる。
任意の容積では、最適PA/TL=最適RRI=Vr/(Dt)
従って、任意の時間tでの最大Cvは、任意のVrで最適RRI=(PA/FL)のとき与えられる。
また、(Vr)/(RRI)比=(Vr)/(PA/TL)=Dtにより、その時の最適速度が決定されることになる。
表X
Claims (127)
- 患者を治療するための装置であって、
治療流体からの、患者に埋め込み可能な治療デバイスの流体の少なくとも部分的な分離を伴って、該埋め込み型治療デバイスのチャンバの中へ治療流体を注入するための注入器を含む、前記装置。 - 眼を治療するための装置であって、
治療流体からの、眼に埋め込み可能な治療デバイスの流体の少なくとも部分的な分離を伴って、該埋め込み型治療デバイスのチャンバの中へ治療流体を注入するための注入器を含む、前記装置。 - 前記少なくとも部分的な分離を提供するために、治療流体は埋め込み型治療デバイスの流体の密度と異なる治療流体密度を有する、請求項2に記載の装置。
- 前記少なくとも部分的な分離を提供するために、治療流体密度が埋め込み型デバイス流体の密度と約1%以上異なる、請求項3に記載の装置。
- 前記少なくとも部分的な分離を提供するために、治療流体密度が埋め込み型デバイス流体の密度と約2%以上異なる、請求項3に記載の装置。
- 前記少なくとも部分的な分離を提供するために、治療流体密度が埋め込み型デバイス流体の密度と約3%以上異なる、請求項3に記載の装置。
- 前記少なくとも部分的な分離を提供するために、治療流体密度が埋め込み型デバイス流体の密度と約30%以下異なる、請求項3に記載の装置。
- 前記少なくとも部分的な分離を提供するために、治療流体密度が埋め込み型デバイス流体の密度と約20%以下異なる、請求項3に記載の装置。
- 前記少なくとも部分的な分離を提供するために、治療流体密度が埋め込み型デバイス流体の密度と約10%以下異なる、請求項3に記載の装置。
- 前記少なくとも部分的な分離を提供するために、埋め込み型デバイス流体の密度に対する治療流体密度の差が約1%〜約30%の範囲内である、請求項3に記載の装置。
- 前記少なくとも部分的な分離を提供するために、埋め込み型デバイス流体の密度に対する治療流体密度の差が約2%〜約20%の範囲内である、請求項3に記載の装置。
- 前記少なくとも部分的な分離を提供するために、埋め込み型デバイス流体の密度に対する治療流体密度の差が約3%〜約10%の範囲内である、請求項3に記載の装置。
- 前記注入器が、治療デバイスの中へ治療流体を通過させる第1の管腔とチャンバから治療流体を受容する第2の管腔とを含む少なくとも1つの針を含み、注入器は、第2の管腔が治療流体から実質的に分離された埋め込み型デバイス流体の部分を受容するように、治療流体がデバイス流体と混合するのを阻止するような流量で治療流体を注入するように構成される、請求項2に記載の装置。
- 前記注入器が、前記少なくとも部分的な分離を提供するような流量で治療流体を注入するように構成される、請求項2に記載の装置。
- 前記注入器が、治療流体密度と異なる治療流体密度に基いて前記少なくとも部分的な分離を提供する速度で治療薬を注入するように構成される、請求項14に記載の装置。
- 前記チャンバが実質的に一定の容積を有する、請求項14に記載の装置。
- 前記実質的に一定の容積が、約1μL〜約100μLの範囲内である、請求項16に記載の装置。
- 前記チャンバが、約15μL〜約75μLの範囲内の実質的に一定の容積を有する、請求項17に記載の装置。
- 前記チャンバが、約25μL〜約75μLの範囲内の実質的に一定の容積を有する、請求項18に記載の装置。
- 前記注入器が、時間をかけてチャンバの中へ治療流体を注入するように構成される、請求項14に記載の装置。
- 前記時間が約1秒〜約30秒の範囲内である、請求項20に記載の装置。
- 前記注入器が約2秒〜約8秒の範囲内の時間をかけてチャンバの中へ治療流体を注入するように構成される、請求項21に記載の装置。
- 前記注入器が、前記少なくとも部分的な分離を提供するのに十分な速度で薬剤を注入する機構、流れに抵抗する構造体、規制部、多孔質構造体、または焼結多孔質構造体のうちの1つ以上を含む、請求項14に記載の装置。
- 前記機構が、液体を前記速度で注入するためのバネ、気体、または液体のうちの1つ以上を含む、請求項23に記載の装置。
- 前記埋め込み型デバイスが治療薬を放出する多孔質構造体を含み、多孔質構造体がある流れ抵抗を有し、治療流体の部分が多孔質構造体を通過するように、前記注入器の流れに抵抗する構造体が、多孔質構造体の該流れ抵抗に比例する流れ抵抗を有する、請求項23に記載の装置。
- 前記埋め込み流体が、約1週間以上治療デバイスに配置された第1の治療流体の残存部分を含み、前記治療流体が第1の治療流体と類似している、請求項2に記載の装置。
- 前記埋め込み型デバイスの流体が、治療デバイスに配置された第1の治療流体の第1の治療薬の第1の量の残存部分と眼の硝子体液の成分とを含む、請求項2に記載の装置。
- 埋め込み型デバイスに配置された第1の治療流体の前記残存部分が前記治療薬の残存量を含み、密度差を付与するために治療薬の残存量が第1の治療薬の第1の量の約半分以下に対応する、請求項27に記載の装置。
- 前記残存部分が残存する安定剤を含み、密度差を付与するために残存する安定剤の量が第1の治療流体の安定剤の第1の量の約半分以下に対応する、請求項27に記載の装置。
- 前記少なくとも部分的な分離を提供するために、硝子体液の1つ以上成分が、治療流体の治療流体密度より小さい埋め込み型治療デバイスの流体の密度に対応する、請求項27に記載の装置。
- 前記治療流体密度が約0.5g/cm3〜約2g/cm3の範囲内であり、埋め込み型デバイス密度が約0.5〜約2g/cm3の範囲内である、請求項2に記載の装置。
- 前記治療流体密度が約1.01〜約1.5g/cm3の範囲内である、請求項2に記載の装置。
- 前記治療流体密度が約1.03〜約1.5g/cm3の範囲内である、請求項2に記載の装置。
- 前記注入器が、前記チャンバを治療薬を含むシリンジへ連結する少なくとも1つの管腔を有する少なくとも1つの針を含む、請求項2に記載の装置。
- 前記少なくとも1つの管腔が、治療流体を埋め込み型デバイスの中へ通過させる第1の管腔と埋め込み型治療デバイスから液体を受容する第2の管腔とを含む、請求項34に記載の装置。
- 前記第1の管腔が第1の開口へ延出し、前記第2の管腔が第2の開口へ延出し、前記少なくとも部分的な分離を促進するために、第1の開口が第2の開口から離間している、請求項35に記載の装置。
- 前記少なくとも部分的な分離を促進するために、治療流体がチャンバの遠位部分へ通過し、かつ埋め込み型治療デバイスの流体がチャンバの近位部分で受容されるように、前記第1の開口が前記第2の開口に対して遠方に配置される、請求項36に記載の装置。
- 第2の管腔を通して受容した治療デバイスの流体を受容する容器をさらに含み、該容器が容器から押出される空気を通過させるベントを含み、第2の開口からベントへ延出する流路を画成するためにベントが該開口に流体密閉状態で連結され、該流路が前記少なくとも部分的な分離を促進するために流れ抵抗を有する、請求項35に記載の装置。
- 前記流路が治療デバイスの流体の流れを阻止する1つ以上の構造を含み、該1つ以上の構造が、第2の開口のサイズ、流路に沿った規制部、流路に沿った多孔質構造体のうちの1つ以上を含む、請求項38に記載の装置。
- 複数の相互連結チャネルを含む注入器多孔質構造体が、前記容器の下流部分で前記流路に沿って設置される、請求項38に記載の装置。
- 埋め込み型デバイスの流体が前記容器の下流部分の流路に沿って設置された注入器多孔質構造体に接触したとき、治療流体が埋め込み型デバイスの多孔質構造体を通過するように、前記注入器多孔質構造体が、埋め込み型デバイスの多孔質構造体よりも大きな液体流れ抵抗を有する、請求項40に記載の装置。
- 前記第2の管腔がベントに連結されており、該ベントが、埋め込み型デバイスの流体がベントを通過するときチャンバに圧力をかけ、かつ治療流体の部分を多孔質構造体を通過させる流れ抵抗を有する、請求項35に記載の装置。
- 前記注入器が、シリンジへ連結するために前記少なくとも1つの針を含むカートリッジを含む、請求項34に記載の装置。
- 前記カートリッジが、前記埋め込み型デバイスの流体からの治療薬流体の少なくとも部分的な分離を促進させるのに十分な流れ抵抗を有するベントを含む、請求項43に記載の装置。
- 前記少なくとも1つの管腔が、埋め込み型デバイスの中へ治療流体を通過させる第1の管腔と、埋め込み型治療デバイスから液体を受容する第2の管腔とを含む、請求項34に記載の装置。
- 前記少なくとも1つの針が第1の針と第2の針とを含む、請求項2に記載の装置。
- 前記少なくとも1つの針が、第1の軸に沿って延出する第1の管腔を有する第1の針と、第2の軸に沿って延出する第2の管腔を有する第2の針とを含み、前記埋め込み型デバイス流体からの治療流体の少なくとも部分的な分離を増大させるために該第1の軸が該第2の軸から分離されている、請求項2に記載の装置。
- 前記少なくとも1つの針が、第1の軸に沿って延出する第1の管腔を有する第1の針と、第1の軸と実質的に同心であるように第1の針に沿って延出する第2の管腔を有する第2の針とを有する二重管腔針を含む、請求項2に記載の装置。
- 前記少なくとも1つの針がその長さに沿って延出する軸を含み、前記少なくとも部分的な分離が、治療製剤が注入されるときの水平に対する該軸の角度に対応する、請求項2に記載の装置。
- 前記少なくとも部分的な分離が、前記水平に対する角度が約10度以上であるとき、治療デバイスに配置される治療流体の量の約1パーセント以上の増加に対応する、請求項49に記載の装置。
- 前記少なくとも部分的な分離が、水平に対する角度が約35度以上であるとき、治療デバイスに配置される治療流体の量の約2パーセント以上の増加に対応する、請求項49に記載の装置。
- 前記注入器が、チャンバ流体の密度に対する治療流体の密度の1パーセント増加が、チャンバに配置される治療流体の量の約1パーセント以上の増加に対応するような前記少なくとも部分的な分離を伴って治療流体を注入するように構成される、請求項2に記載の装置。
- 前記注入器が、チャンバ流体の密度に対する治療流体の密度の1パーセント増加が、容器の中へ治療流体を注入することによりチャンバに配置される治療流体の量の約2パーセント以上の増加に対応するような前記少なくとも部分的な分離を伴って治療流体を注入するように構成される、請求項2に記載の装置。
- 前記注入器が、チャンバの流体の密度に対する治療流体の密度の3パーセント増加が、容器の中へ治療流体を注入することによりチャンバに配置される治療流体の量の約4パーセント以上の増加に対応するような前記少なくとも部分的な分離を伴って治療流体を注入するように構成される、請求項2に記載の装置。
- 前記チャンバに配置される治療流体の量の約1パーセント以上の増加が、水平に対する注入角度に対応する、請求項52に記載の装置。
- 前記水平に対する注入角度が、水平に対して約10度以上対応する、請求項55に記載の装置。
- 前記水平に対する注入角度が、水平に対して約15度以上対応する、請求項56に記載の装置。
- 前記埋め込み型デバイスの流体が、水と、眼の硝子体液の成分と、前記治療薬とからなる液体を含む、請求項2に記載の装置。
- 前記埋め込み型デバイスの流体が安定剤を含む、請求項58に記載の装置。
- 前記治療流体が、水と前記治療薬とからなる液体を含む、請求項2に記載の装置。
- 前記治療流体が安定剤を含む、請求項60に記載の装置。
- 前記埋め込み型デバイスの流体が、約1μL/秒〜約200μL/秒の範囲内の速度で押出される、請求項2に記載の装置。
- 前記埋め込み型デバイスの流体が、約2μL/秒〜約100μL/秒の範囲内の速度で押出される、請求項62に記載の装置。
- 前記埋め込み型デバイスの流体が、約5μL/秒〜約50μL/秒の範囲内の速度で押出される、請求項63に記載の装置。
- 前記埋め込み型デバイスの流体が、約70%以上の効率で押出される、請求項2に記載の装置。
- 前記埋め込み型デバイスの流体が、約80%以上の効率で押出される、請求項65に記載の装置。
- 前記埋め込み型デバイスの流体が、約90%以上の効率で押出される、請求項66に記載の装置。
- 前記弁が、開口に連結されたフロート弁またはピストンに連結された硬質停止部のうちの1つ以上を含む、請求項2に記載の装置。
- 前記注入器が、シリンジへ連結する前記少なくとも1つの針を含むカートリッジを含む、請求項34に記載の装置。
- 眼を治療するための装置であって、
治療流体からの、眼に埋め込み可能な治療デバイスの流体の少なくとも部分的な分離を伴って、埋め込み型治療デバイスのチャンバの中へ治療流体を注入するためのカートリッジを含む、前記装置。 - 前記カートリッジが、シリンジへ連結する連結器と、ベントと、少なくとも1つの針とを含み、該少なくとも1つの針が第1の管腔と第2の管腔を含み、該第1の管腔はシリンジから治療流体を通過させるために連結器からチャンバの中へ延出するサイズを有し、該第2の管腔は該ベントを含みかつ収集容器で埋め込み型治療デバイスの流体を受容するためにベントをチャンバの中に配置しかつ収集容器へ延出するサイズを有し、約70%以上のチャンバの補充効率を付与するようにカートリッジを治療流体の密度に適応させる、請求項70に記載の装置。
- 前記ベントが、治療デバイス流体が押出されるときある量の治療流体を埋め込み型デバイスの多孔質構造体を通して通過させるために、該多孔質構造体の流れ抵抗に対応する流れ抵抗を有する、請求項71に記載の装置。
- 前記量の治療流体を多孔質構造体を通して通過させるために、前記ベント構造体の流れ抵抗が多孔質構造体の流れ抵抗に比例する、請求項72に記載の装置。
- 前記量の治療流体を多孔質構造体を通して通過させるために、前記ベント構造体の流れ抵抗が多孔質構造体の流れ抵抗より実質的に大きい、請求項72に記載の装置。
- 前記ベント構造体が、ベント構造体の流れ抵抗の実質的部分を付与するサイズのチャネルを含む、請求項74に記載の装置。
- 前記ベント構造体が、ベント構造体の流れ抵抗の実質的部分を付与する多孔質材料を含む、請求項74に記載の装置。
- 前記少なくとも1つの針が第1の針と第2の針とを含む、請求項71に記載の装置。
- 前記少なくとも1つの針が二重管腔針を含む、請求項71に記載の装置。
- 患者を治療するための装置であって、
多孔質構造体に連結された貫通性障壁とチャンバとを含む埋め込み型デバイスを含み、該デバイスが、破壊されることなくチャンバおよび多孔質構造体に約50PSI以上の圧力を受けることが可能である、前記装置。 - 前記デバイスが、破壊されることなくチャンバ、貫通性障壁、および多孔質構造体に約100PSI以上の圧力を受けることが可能である、請求項79に記載の装置。
- 前記デバイスが、破壊されることなくチャンバ、貫通性障壁、および多孔質構造体に約200PSI以上の圧力を受けることが可能である、請求項79に記載の装置。
- 患者を治療するための装置であって、
多孔質構造体に連結された貫通性障壁とチャンバとを含む埋め込み型デバイスを含み、該チャンバが近位端および遠位端を含み、注入または吸引のうちの1つ以上でチャンバに配置される治療流体の量の増加で、該多孔質構造体がチャンバの遠位から離間して配置される、前記装置。 - 患者を治療するための装置であって、
リザーバチャンバと流体分離器とを含む治療デバイスを含み、該流体分離器はデバイスの中へ注入された治療流体を埋め込み型デバイスの流体から分離するためにデバイスのリザーバチャンバ内にある、前記装置。 - 前記流体分離器が、治療デバイスのリザーバチャンバ内にある容器または可動型流体分離器のうちの1つ以上を含む、請求項83に記載の装置。
- 患者を治療するための装置であって、
眼に埋め込み可能なデバイスの流体を治療流体で置換するために、該デバイスのチャンバの中へ空気を注入するよう構成される注入器を含む、前記装置。 - 患者を治療するための装置であって、
先端部を含む針と停止部とを含む注入用デバイス;および
多孔質構造体に連結された貫通性障壁とチャンバとを含む埋め込み型デバイス
を含み、治療流体の流れを分流する構造体がチャンバ内に設置され、停止部は、停止部が眼の結膜に接触したとき針の先端部と該構造体との間に間隙が存在するように先端部をチャンバ内に配置するよう構成される、前記装置。 - 眼を治療するための装置であって、
眼を治療するための治療薬を含む治療流体を含有する容器へ連結する連結器;
治療流体を通過させる第1の管腔と治療デバイスから流体を受容する第2の管腔とを含む少なくとも1つの針であって、第1の管腔が第1の開口へ延出し第2の管腔が第2の開口へ延出するもの;および
眼に埋め込み可能な治療デバイスからの流体を受容する容器であって、第2の管腔が第2の開口から該容器へ延出する流路を画成するために該容器へ流体密閉状態で連結されるもの
を含み、治療流体が埋め込み型デバイスの流体を押出すとき、埋め込み型デバイスの流体から治療流体を少なくとも部分的に分離するために、該流路が抵抗を含む、前記装置。 - 治療薬で眼を治療するための装置であって、
眼に埋め込み可能な治療デバイスのチャンバの中へ該治療薬を含む治療流体を注入するための開口へ延出する管腔を含む少なくとも1つの針;および
治療デバイスの流体を受容するベント構造体であって、治療デバイスの流体の流れに対する抵抗を有するもの
を含む、前記装置。 - ある量の治療流体を治療デバイスの多孔質構造体を通して通過させるために、前記ベント構造体の流れ抵抗が多孔質構造体の流れ抵抗に対応する、請求項88に記載の装置。
- 前記量が治療デバイスの中への注入量の約0.1パーセント以上である、請求項89に記載の装置。
- 前記ベント構造体の流れ抵抗を付与するために、ベント構造体がベントおよびベントに連結されたチャネルを含む、請求項89に記載の装置。
- 停止部をさらに含み、停止部は眼の結膜に締結する下面を含み、前記少なくとも1つの針が、該下面が結膜に締結したときリザーバチャンバの中に開口とベントとを配置するような距離で、該下面から開口への軸に沿って延出する、請求項91に記載の装置。
- カートリッジをさらに含み、該カートリッジが前記少なくとも1つの針と前記ベント構造体とを含む、請求項91に記載の装置。
- 前記カートリッジがシリンジへ連結する連結器を含み、前記少なくとも1つの針が第1の管腔および第2の管腔を含み、該第1の管腔はシリンジから治療流体を通過させるために連結器からチャンバの中へ延出するサイズを有し、該第2の管腔はベントへ延出しかつ収集容器で埋め込み型治療デバイスの流体を受容するためにベントをチャンバの中に配置しかつ収集容器へ延出するサイズを有し、約70%以上のチャンバの補充効率を付与するようにカートリッジを治療流体の密度に適応させる、請求項93に記載の装置。
- 前記量の治療流体を埋め込み型デバイスの多孔質構造体を通して通過させるために、前記ベント構造体の流れ抵抗が多孔質構造体の流れ抵抗より実質的に大きい、請求項94に記載の装置。
- 前記量の治療流体を埋め込み型デバイスの多孔質構造体を通して通過させるために、前記ベント構造体の流れ抵抗が多孔質構造体の流れ抵抗よりも実質的に小さい、請求項94に記載の装置。
- 前記少なくとも1つの針が第1の針と第2の針とを含む、請求項94に記載の装置。
- 前記少なくとも1つの針が二重管腔針を含む、請求項94に記載の装置。
- 埋め込み型デバイスで患者を治療する方法であって、
患者に埋め込まれた治療デバイスのチャンバに入る治療流体がチャンバの流体から少なくとも部分的に分離されるように、該チャンバの中へ治療流体を注入することを含む、前記方法。 - 眼を治療する方法であって、
眼に埋め込まれた治療デバイスのチャンバに入る治療流体がチャンバの流体から少なくとも部分的に分離されるように、該チャンバの中へ治療流体を注入することを含む、前記方法。 - 前記治療流体がある密度を有し、前記デバイスの流体が治療流体の該密度と異なる密度を有する、請求項100に記載の方法。
- 前記治療デバイスが近位端に貫通性障壁を遠位端に多孔質構造体を含み、貫通性障壁と多孔質構造体との間を延出する軸を有し、前記少なくとも部分的な分離を提供するために該軸が水平から離間して配向されている、請求項100に記載の方法。
- 多孔質構造体が貫通性障壁の上方に位置するように前記患者を配置する、請求項102に記載の方法。
- 埋め込まれたデバイスが眼の毛様体扁平部領域に設置されているとき、多孔質構造体が貫通性障壁の上方に位置するように前記患者が頭部を傾斜させて椅子にもたれている、請求項102に記載の方法。
- 多孔質構造体が貫通性障壁の下方に位置するように前記患者を配置する、請求項102に記載の方法。
- 埋め込まれた治療デバイスの流体から治療流体を少なくとも部分的に分離するために、前記治療流体を上向きに注入する、請求項100に記載の方法。
- 埋め込まれた治療デバイスの流体から治療流体を少なくとも部分的に分離するために、前記治療流体を下向きに注入する、請求項100に記載の方法。
- 少なくとも1つの針の第1の開口が少なくとも1つの針の第2の開口の下方に配置されるように、第1の開口がチャンバの遠位部分に配置され第2の開口がチャンバの近位部分に配置されるように、少なくとも1つの針を埋め込まれたデバイスの貫通性障壁を通して前進させ、チャンバ内の治療デバイス流体から治療流体を少なくとも部分的に分離するために、前記治療流体が埋め込まれたデバイス流体よりも大きな密度を有しかつ第2の開口の下方にある第1の開口を通過する、請求項100に記載の方法。
- 前記治療流体が、治療流体の密度変化率が、治療流体の密度変化率よりも大きなチャンバの充填効率の変化率に対応するように、前記少なくとも部分的な分離を伴って注入される、請求項100に記載の方法。
- 眼を治療する方法であって、
眼に埋め込まれた治療デバイスの流体を治療流体で少なくとも部分的に置換するために、埋め込まれた治療デバイスのチャンバの中へ空気を注入することを含む、前記方法。 - 請求項1〜87のいずれかに記載の装置をさらに含む、請求項100または110に記載の方法。
- 患者の中へ治療薬を注入する装置であって、
患者の外部組織を貫通可能かつ患者内のある深さまで延出可能な少なくとも1つの針;
該少なくとも1つの針に連結された、治療薬を保持する1つ以上のチャンバ;および
前記深さまでの該少なくとも1つの針の針貫通を指示するために、針の回りを少なくとも部分的に延出する可変形視認用インジケータ
を含む、前記装置。 - 前記可変形視認用インジケータが組織に接触する前の第1の断面幅を有する第1の構成と第2の断面幅を有する第2の構成とを有し、視認用インジケータの視認性を高めて針が前記深さにあることを指示するために第2の断面幅が第1の断面幅よりも大きい、請求項112に記載の装置。
- 前記少なくとも1つの針がある幅を有する環状支持構造体で支持され、前記可変形視認用インジケータが該少なくとも1つの針の周りを延出する環状可変形構造を含み、第1の断面幅が前記幅よりも小さく、第2の断面幅が前記幅よりも大きい、請求項112に記載の装置。
- 前記可変形視認用インジケータが、前記少なくとも1つの針を前記深さに維持する力で針が該深さに挿入されていることを指示するための変形剛性率を有する、請求項112に記載の装置。
- 前記可変形視認用インジケータが、前記針が前記深さにあることをユーザに指示するための可視色を有する、請求項112に記載の装置。
- 前記少なくとも1つの針が、視認用インジケータから第1の距離に設置される第1の開口まで視認用インジケータから延出する第1の管腔と、視認用インジケータから第2の距離に設置される第2の開口まで視認用インジケータから延出する第2の管腔とを含み、視認用インジケータが、第1の開口が第1の深さにあり、第2の開口が第2の深さにあることを指示する、請求項112に記載の装置。
- 前記少なくとも1つの針がゲージが約25以上のシリコン針を含む、請求項112に記載の装置。
- 前記少なくとも1つの針を前記深さに維持する力で針が前記深さまで挿入されていることを指示するために、前記可変形視認用インジケータが、約5〜約30の範囲内であるショアA硬度を含む、請求項112に記載の装置。
- 埋め込み型治療デバイスを更に含み、埋め込み型治療デバイスはある量の治療薬を保持するリザーバチャンバを有し、リザーバチャンバは治療デバイスの軸に沿って延出し、前記少なくとも1つの針は、前記視認用インジケータが変形して針が前記距離に位置していることを指示するとき開口がリザーバチャンバの中に位置しているように可変形視認用インジケータから離れた開口へ延出する管腔を有する、請求項112に記載の装置。
- 前記埋め込み型治療デバイスが、長期間にわたって治療量の治療薬を放出する多孔質構造体を含む、請求項120に記載の装置。
- 前記多孔質構造体が、約1ヵ月以上の長期間にわたって治療薬を放出するように約0.5以下の放出速度指数を含む、請求項121に記載の装置。
- 前記視認用インジケータが変形したとき前記開口がリザーバチャンバの近位半部に位置している、請求項120に記載の装置。
- 前記視認用インジケータが変形したとき前記開口がリザーバチャンバの遠位半部に位置している、請求項120に記載の装置。
- 組織を有する患者を治療する方法であって、
可変形視認用インジケータが組織へ連結しかつ少なくとも1つの針がある深さにあることを指示するために変形するように、組織の中へ少なくとも1つの針を前進させること;および
視認用インジケータが変形したとき該深さにある少なくとも1つの針の管腔を通して治療薬が注入されるように、少なくとも1つの針に連結された1つ以上のチャンバから治療薬を注入すること
を含む、前記方法。 - 前記可変形視認用インジケータが、組織に接触する前の第1の断面幅を有する第1の構成と、インジケータが外部貫通性組織に連結されたときの第2の断面幅を有する第2の構成とを含み、視認用インジケータの視認性を向上させて前記深さに針があることを指示するために、第2の断面幅が第1の断面幅より大きい、請求項125に記載の方法。
- 埋め込み型治療デバイスを更に含み、埋め込み型治療デバイスがある量の治療薬を保持するリザーバチャンバを有し、リザーバチャンバが結膜と強膜との間に配置するためのサイズの厚さと幅を有し、前記少なくとも1つの針は、視認用インジケータが変形して針が前記距離に位置していることを指示するとき開口がリザーバチャンバの中に位置しているように可変形視認用インジケータから離れた開口へ延出する管腔を有する、請求項112に記載の装置。
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37115410P | 2010-08-05 | 2010-08-05 | |
US37116910P | 2010-08-05 | 2010-08-05 | |
US61/371,154 | 2010-08-05 | ||
US61/371,169 | 2010-08-05 | ||
US201161495251P | 2011-06-09 | 2011-06-09 | |
US61/495,251 | 2011-06-09 | ||
US201161495718P | 2011-06-10 | 2011-06-10 | |
US61/495,718 | 2011-06-10 | ||
US201161499095P | 2011-06-20 | 2011-06-20 | |
US61/499,095 | 2011-06-20 | ||
US201161501021P | 2011-06-24 | 2011-06-24 | |
US61/501,021 | 2011-06-24 | ||
US201161504038P | 2011-07-01 | 2011-07-01 | |
US61/504,038 | 2011-07-01 | ||
PCT/US2011/046812 WO2012019136A2 (en) | 2010-08-05 | 2011-08-05 | Injector apparatus and method for drug delivery |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016244154A Division JP6326124B2 (ja) | 2010-08-05 | 2016-12-16 | 薬剤送達のための注入用装置 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013532576A true JP2013532576A (ja) | 2013-08-19 |
JP2013532576A5 JP2013532576A5 (ja) | 2014-09-25 |
JP6063382B2 JP6063382B2 (ja) | 2017-01-18 |
Family
ID=45560101
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013523370A Active JP6063382B2 (ja) | 2010-08-05 | 2011-08-05 | 治療薬を眼の埋め込み体へと注入するためのシステム |
JP2016244154A Active JP6326124B2 (ja) | 2010-08-05 | 2016-12-16 | 薬剤送達のための注入用装置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016244154A Active JP6326124B2 (ja) | 2010-08-05 | 2016-12-16 | 薬剤送達のための注入用装置 |
Country Status (17)
Country | Link |
---|---|
US (5) | US9033911B2 (ja) |
EP (2) | EP2600930B1 (ja) |
JP (2) | JP6063382B2 (ja) |
CN (2) | CN105435338B (ja) |
AU (3) | AU2011285545B2 (ja) |
CA (1) | CA2807535C (ja) |
DK (1) | DK2600930T3 (ja) |
ES (1) | ES2888906T3 (ja) |
HR (1) | HRP20210587T1 (ja) |
HU (1) | HUE054113T2 (ja) |
LT (1) | LT2600930T (ja) |
PL (1) | PL2600930T3 (ja) |
PT (1) | PT2600930T (ja) |
RS (1) | RS61601B1 (ja) |
SG (1) | SG187730A1 (ja) |
SI (1) | SI2600930T1 (ja) |
WO (1) | WO2012019136A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019510581A (ja) * | 2016-04-05 | 2019-04-18 | フォーサイト・ビジョン フォー・インコーポレーテッドForsight Vision4, Inc. | 移植可能な眼薬送達デバイス |
JP2021504071A (ja) * | 2017-11-21 | 2021-02-15 | フォーサイト・ビジョン4・インコーポレーテッドForSight Vision4, Inc. | 膨張可能ポート送達システムのための流体交換装置及びその使用方法 |
JP2021094405A (ja) * | 2014-11-10 | 2021-06-24 | フォーサイト・ビジョン フォー・インコーポレーテッドForsight Vision4, Inc. | 拡張可能な薬物送達デバイスおよび使用方法 |
JP2021522180A (ja) * | 2018-04-17 | 2021-08-30 | アウトルック セラピューティクス,インコーポレイティド | ベバシズマブの緩衝製剤を用いる疾患の治療方法 |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US7291125B2 (en) | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
WO2010088258A2 (en) | 2009-01-28 | 2010-08-05 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
PL2391419T3 (pl) | 2009-01-29 | 2019-12-31 | Forsight Vision4, Inc. | Dostarczanie leku do tylnego odcinka |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US9795404B2 (en) | 2009-12-31 | 2017-10-24 | Tenex Health, Inc. | System and method for minimally invasive ultrasonic musculoskeletal tissue treatment |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US9408746B2 (en) | 2010-03-31 | 2016-08-09 | Ocuject, Llc | Device and method for intraocular drug delivery |
US9320647B2 (en) | 2010-03-31 | 2016-04-26 | Ocuject, Llc | Device and method for intraocular drug delivery |
WO2012019136A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Injector apparatus and method for drug delivery |
WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
SI2600812T1 (sl) | 2010-08-05 | 2021-12-31 | ForSight Vision4, Inc., | Naprava za zdravljenje očesa |
EP3520749A1 (en) | 2010-10-15 | 2019-08-07 | Clearside Biomedical, Inc. | Device for ocular access |
US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
RS61758B1 (sr) | 2011-09-16 | 2021-05-31 | Forsight Vision4 Inc | Aparati za razmenu tečnosti |
RU2768492C2 (ru) | 2011-11-18 | 2022-03-24 | Ридженерон Фармасьютикалз, Инк. | Полимерные белковые микрочастицы |
WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US9421129B2 (en) | 2012-04-02 | 2016-08-23 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
US9504603B2 (en) | 2012-04-02 | 2016-11-29 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9149291B2 (en) | 2012-06-11 | 2015-10-06 | Tenex Health, Inc. | Systems and methods for tissue treatment |
US11406415B2 (en) | 2012-06-11 | 2022-08-09 | Tenex Health, Inc. | Systems and methods for tissue treatment |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
CA2905496A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9597227B2 (en) * | 2013-03-15 | 2017-03-21 | Abbott Medical Optics Inc. | Trans-sclera portal for delivery of therapeutic agents |
CN105246438B (zh) | 2013-03-28 | 2018-01-26 | 弗赛特影像4股份有限公司 | 用于输送治疗物质的眼科植入物 |
CN105246529B (zh) | 2013-05-03 | 2019-06-14 | 科尼尔赛德生物医学公司 | 用于眼部注射的设备和方法 |
WO2014197317A1 (en) | 2013-06-03 | 2014-12-11 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
WO2015085234A1 (en) | 2013-12-06 | 2015-06-11 | Forsight Vision4, Inc. | Implantable therapeutic devices |
JP6369551B2 (ja) * | 2014-02-26 | 2018-08-08 | パウダー ファーマシューティカルズ インコーポレイテッド | 粒子を送達する装置 |
US10426659B2 (en) | 2014-04-23 | 2019-10-01 | Vacu-Site Medical, Inc. | Vacuum-assisted drug delivery device and method |
US11351347B2 (en) | 2014-04-23 | 2022-06-07 | Vacu-Site Medical, Inc. | Vacuum-assisted drug delivery device and method |
US11045352B2 (en) * | 2014-05-12 | 2021-06-29 | Gholam A. Peyman | Methods for treatment of dry eye and other acute or chronic inflammatory processes |
US11648261B2 (en) | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
US10925889B2 (en) | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
EP3148491B1 (en) | 2014-05-29 | 2020-07-01 | Glaukos Corporation | Implants with controlled drug delivery features and manufacturing method for said implants |
KR102511477B1 (ko) * | 2014-06-17 | 2023-03-16 | 클리어사이드 바이오메디컬, 인코포레이드 | 안구 후부 질환을 치료하기 위한 방법 및 디바이스 |
RU2695563C2 (ru) | 2014-07-15 | 2019-07-24 | Форсайт Вижн4, Инк. | Способ и устройство для доставки глазного имплантата |
CN107106551A (zh) | 2014-08-08 | 2017-08-29 | 弗赛特影像4股份有限公司 | 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法 |
US9962181B2 (en) | 2014-09-02 | 2018-05-08 | Tenex Health, Inc. | Subcutaneous wound debridement |
US20160096040A1 (en) * | 2014-10-02 | 2016-04-07 | Tenex Health, Inc. | Laminated Needles and Methods of Making and Using Same |
US10031348B2 (en) | 2014-10-15 | 2018-07-24 | California Institute Of Technology | Contact lens with metered liquid system |
DK3220996T3 (da) | 2014-11-20 | 2022-03-21 | Viacyte Inc | Instrumenter og fremgangsmåder til indfyldning af celler i implanterbare indretninger |
EP4070830A1 (en) * | 2015-01-09 | 2022-10-12 | Becton Dickinson and Company Limited | Infusion adapter |
US10610350B2 (en) * | 2015-04-19 | 2020-04-07 | Halkey-Roberts Corporation | Spring-powered, hydraulically-operated intraocular lens inserter |
US9763689B2 (en) | 2015-05-12 | 2017-09-19 | Tenex Health, Inc. | Elongated needles for ultrasonic applications |
WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
CN113827704B (zh) | 2015-10-16 | 2024-07-12 | 瑞泽恩制药公司 | 稳定蛋白质组合物 |
EA038755B1 (ru) | 2015-11-12 | 2021-10-14 | Грейбаг Вижн, Инк. | Агрегирующие микрочастицы для обеспечения замедленного высвобождения терапевтического агента для внутриглазной доставки |
MX2018006234A (es) | 2015-11-20 | 2018-08-14 | Forsight Vision4 Inc | Estructuras porosas para dispositivos de suministro de medicamentos de liberacion prolongada. |
EP3442479A1 (en) | 2016-04-20 | 2019-02-20 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
WO2017192565A1 (en) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
US11213430B2 (en) | 2016-05-26 | 2022-01-04 | Cochlear Limited | Inner ear plug |
AU2017290593A1 (en) | 2016-06-27 | 2019-01-03 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
CN110177527B (zh) | 2016-08-12 | 2022-02-01 | 科尼尔赛德生物医学公司 | 用于调节药剂递送用针的插入深度的装置和方法 |
US11850330B2 (en) | 2016-11-10 | 2023-12-26 | Organovo, Inc. | Bioprinted hair follicles and uses thereof |
US20200375847A1 (en) * | 2017-01-03 | 2020-12-03 | Haley Lee Frame | Anesthetics needle device to facilitate the use of buffered anesthetics |
US11612888B2 (en) | 2017-01-04 | 2023-03-28 | The Research Foundation For The State University Of New York | Biomarker detection device |
CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
BR112019019452A2 (pt) | 2017-03-23 | 2020-04-14 | Graybug Vision Inc | composto, e, uso de um composto |
WO2018204515A1 (en) | 2017-05-02 | 2018-11-08 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
AU2018265415A1 (en) | 2017-05-10 | 2019-10-31 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
CN118542771A (zh) * | 2018-04-16 | 2024-08-27 | 温州医科大学 | 一种眼表植入物注射装置 |
US11523939B2 (en) | 2018-05-22 | 2022-12-13 | California Institute Of Technology | Miniature fixed and adjustable flow restrictor for the body |
EP3801466B1 (en) * | 2018-06-11 | 2024-01-17 | California Institute of Technology | Eye treatment device having a ring like shape |
EP3841086A4 (en) | 2018-08-20 | 2022-07-27 | Achillion Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D |
JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
CN110152120A (zh) * | 2019-07-02 | 2019-08-23 | 北京林特医药科技有限公司 | 一种外c提升注射方法 |
TW202146412A (zh) | 2020-03-05 | 2021-12-16 | 美商C4醫藥公司 | 用於標靶降解brd9之化合物 |
US11083557B1 (en) * | 2020-05-01 | 2021-08-10 | Secada Medical Llc | Bone graft containment system |
CN112494325B (zh) * | 2020-11-19 | 2021-08-24 | 联赢医疗科技有限公司 | 一种可自动调配药液的输液机器人 |
USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
WO2024112747A1 (en) * | 2022-11-23 | 2024-05-30 | Iantrek, Inc. | Devices and systems for cutting, loading, and delivering biologic intraocular implants for increased aqueous outflow and lowering of intraocular pressure |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2646042A (en) * | 1951-05-18 | 1953-07-21 | Hu Quang Hsi | Medical apparatus |
JPH08509636A (ja) * | 1993-04-30 | 1996-10-15 | アラーガン、インコーポレイテッド | 接着性粘弾性物質の除去の為の器具及び方法 |
WO2009089094A2 (en) * | 2008-01-03 | 2009-07-16 | University Of Southern California | Implantable drug-delivery devices, and apparatus and methods for refilling the devices |
WO2009137777A2 (en) * | 2008-05-08 | 2009-11-12 | Replenish Pumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
WO2010078063A1 (en) * | 2009-01-02 | 2010-07-08 | Alcon Research, Ltd. | In-situ refillable ophthalmic implant |
Family Cites Families (449)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1747814A (en) | 1927-10-03 | 1930-02-18 | Gulf Production Company | Automatic switcher device for oil-storage tanks |
US2585815A (en) | 1947-01-16 | 1952-02-12 | Mclintock Duncan Menzies | Injection syringe |
US2564977A (en) | 1949-01-19 | 1951-08-21 | Hu Quang Hsi | Medical injecting apparatus |
US2886497A (en) | 1957-04-12 | 1959-05-12 | United States Steel Corp | Method for determining the permeability of steel to hydrogen |
US3232117A (en) | 1962-09-14 | 1966-02-01 | Roger Gilmont Instr Inc | Micrometer buret |
US3416530A (en) | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
US3612089A (en) | 1968-10-28 | 1971-10-12 | Torit Corp | Vacuum reactivator |
US3618604A (en) | 1969-06-09 | 1971-11-09 | Alza Corp | Ocular insert |
US3641237A (en) | 1970-09-30 | 1972-02-08 | Nat Patent Dev Corp | Zero order release constant elution rate drug dosage |
US4034756A (en) | 1971-01-13 | 1977-07-12 | Alza Corporation | Osmotically driven fluid dispenser |
US3831583A (en) | 1971-03-05 | 1974-08-27 | Univ California | Implantable bulb for inflation of surgical implements |
US3734095A (en) * | 1971-05-21 | 1973-05-22 | L Santomieri | Fluid infusion |
US3995635A (en) | 1971-09-09 | 1976-12-07 | Alza Corporation | Ocular insert |
US3828777A (en) | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
US3845201A (en) | 1972-04-24 | 1974-10-29 | S Loucas | Solid state ophthalmic medication delivery method |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3914402A (en) | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
US4179497A (en) | 1973-12-17 | 1979-12-18 | Merck & Co., Inc. | Solid state ophthalmic medication |
US3902495A (en) | 1974-01-28 | 1975-09-02 | Cavitron Corp | Flow control system |
US3961628A (en) | 1974-04-10 | 1976-06-08 | Alza Corporation | Ocular drug dispensing system |
US3949748A (en) | 1974-09-26 | 1976-04-13 | Oscar Malmin | Injection syringe having aspirating and metering capabilities |
US3949750A (en) | 1974-10-07 | 1976-04-13 | Freeman Jerre M | Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same |
US3926188A (en) | 1974-11-14 | 1975-12-16 | Alza Corp | Laminated drug dispenser |
US4142526A (en) | 1974-12-23 | 1979-03-06 | Alza Corporation | Osmotic releasing system with means for changing release therefrom |
US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
NL188266C (nl) | 1975-07-29 | 1992-05-18 | Merck & Co Inc | Werkwijze ter bereiding van een oogheelkundig inplantaat. |
US3977404A (en) | 1975-09-08 | 1976-08-31 | Alza Corporation | Osmotic device having microporous reservoir |
US4034758A (en) | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
US4014333A (en) | 1975-09-22 | 1977-03-29 | Mcintyre David J | Instrument for aspirating and irrigating during ophthalmic surgery |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4014334A (en) | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
US4111203A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
US4111201A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
US4186184A (en) | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
US4220152A (en) | 1978-05-08 | 1980-09-02 | Pfizer Inc. | Delivery system |
US4220153A (en) | 1978-05-08 | 1980-09-02 | Pfizer Inc. | Controlled release delivery system |
US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4298000A (en) | 1978-11-08 | 1981-11-03 | Minnesota Mining And Manufacturing Company | Fluid dispensing device |
US4300557A (en) | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
DE3068986D1 (en) | 1980-01-28 | 1984-09-27 | Merck & Co Inc | Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors |
US4309776A (en) | 1980-05-13 | 1982-01-12 | Ramon Berguer | Intravascular implantation device and method of using the same |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4484922A (en) | 1981-06-25 | 1984-11-27 | Rosenwald Peter L | Occular device |
US4439198A (en) | 1981-07-09 | 1984-03-27 | University Of Illinois Foundation | Biodegradable ocular insert for controlled delivery of ophthalmic medication |
US4730013A (en) | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
US4475916A (en) | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4519801A (en) | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
US4673405A (en) | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
US4883459A (en) | 1983-07-29 | 1989-11-28 | Reynaldo Calderon | Retrograde perfusion |
US4774091A (en) | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
US4777049A (en) | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
US4634418A (en) | 1984-04-06 | 1987-01-06 | Binder Perry S | Hydrogel seton |
US4851228A (en) | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US4634427A (en) | 1984-09-04 | 1987-01-06 | American Hospital Supply Company | Implantable demand medication delivery assembly |
US5053030A (en) | 1984-11-07 | 1991-10-01 | Herrick Robert S | Intracanalicular implant for horizontal canalicular blockade treatment of the eye |
US5049142A (en) | 1984-11-07 | 1991-09-17 | Herrick Robert S | Intracanalicular implant for horizontal canalicular blockade treatment of the eye |
US4712550A (en) | 1985-04-08 | 1987-12-15 | Sinnett Kevin B | Retinal tack |
US4609374A (en) | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
US4693886A (en) | 1985-04-22 | 1987-09-15 | Alza Corporation | Osmotic device with inert core |
EP0201611A1 (de) | 1985-05-10 | 1986-11-20 | B. Braun-SSC AG | Zwei-Kanülen-Spritze |
US4781675A (en) | 1985-11-27 | 1988-11-01 | White Thomas C | Infusion cannula |
DE3672981D1 (de) | 1985-11-27 | 1990-08-30 | Thomas C White | Gewebeimplantierbare fluessigkeitsverteileinrichtung. |
US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
US5322691A (en) | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US5147647A (en) | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
WO1988004573A1 (en) | 1986-12-23 | 1988-06-30 | The Liposome Company, Inc. | Liposome preparation and antibiotic |
US4853229A (en) | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
JP2702953B2 (ja) | 1988-01-30 | 1998-01-26 | オリンパス光学工業株式会社 | 薬液含浸セラミックス |
US4865846A (en) | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
US5174999A (en) | 1988-12-13 | 1992-12-29 | Alza Corporation | Delivery system comprising fluid ingress and drug egress |
WO1990007575A1 (en) | 1988-12-30 | 1990-07-12 | Anderson David M | Stabilized microporous materials and hydrogel materials |
US5141748A (en) | 1989-02-17 | 1992-08-25 | Hoffmann-La Roche, Inc. | Implant drug delivery device |
US5098443A (en) | 1989-03-23 | 1992-03-24 | University Of Miami | Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents |
US4979938A (en) | 1989-05-11 | 1990-12-25 | Iomed, Inc. | Method of iontophoretically treating acne, furuncles and like skin disorders |
US5817075A (en) * | 1989-08-14 | 1998-10-06 | Photogenesis, Inc. | Method for preparation and transplantation of planar implants and surgical instrument therefor |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5100392A (en) * | 1989-12-08 | 1992-03-31 | Biosynthesis, Inc. | Implantable device for administration of drugs or other liquid solutions |
US5171270A (en) | 1990-03-29 | 1992-12-15 | Herrick Robert S | Canalicular implant having a collapsible flared section and method |
US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5128145A (en) | 1990-06-13 | 1992-07-07 | Alza Corporation | Dosage form for Parkinson's disease, spasticity and muscle spasms |
US5238687A (en) | 1990-07-11 | 1993-08-24 | Alza Corporation | Delivery device with a protective sleeve |
US5084021A (en) | 1990-11-02 | 1992-01-28 | Baldwin Brian E | Patient controlled infusion apparatus and method |
US5273530A (en) * | 1990-11-14 | 1993-12-28 | The University Of Rochester | Intraretinal delivery and withdrawal instruments |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5364343A (en) * | 1991-03-06 | 1994-11-15 | D.D. S.R.L. | Irrigation device for use in ear canals for therapeutic or hygienic purposes |
AU650113B2 (en) | 1991-04-05 | 1994-06-09 | Eli Lilly And Company | Sustained release capsule and formulations |
US5334189A (en) | 1991-06-03 | 1994-08-02 | Wade Stephen E | Device for controlled diffusion of a chemical substance |
US5282829A (en) | 1991-08-15 | 1994-02-01 | United States Surgical Corporation | Hollow body implants |
FR2682090B1 (fr) | 1991-10-03 | 1993-12-31 | Holzstoff Holding Sa | Systeme-reservoir pour diffusion prolongee d'un principe actif. |
US5681572A (en) | 1991-10-18 | 1997-10-28 | Seare, Jr.; William J. | Porous material product and process |
US5830492A (en) | 1992-02-24 | 1998-11-03 | Encelle, Inc. | Bioartificial devices and cellular matrices therefor |
US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
US5322504A (en) * | 1992-05-07 | 1994-06-21 | United States Surgical Corporation | Method and apparatus for tissue excision and removal by fluid jet |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
US5576480A (en) | 1992-11-06 | 1996-11-19 | Pall Corporation | System and method for testing the integrity of porous elements |
US5419521A (en) * | 1993-04-15 | 1995-05-30 | Matthews; Robert J. | Three-axis pedestal |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
CA2140053C (en) | 1994-02-09 | 2000-04-04 | Joel S. Rosenblatt | Collagen-based injectable drug delivery system and its use |
US5985328A (en) | 1994-03-07 | 1999-11-16 | Regents Of The University Of California | Micromachined porous membranes with bulk support |
US5770076A (en) | 1994-03-07 | 1998-06-23 | The Regents Of The University Of California | Micromachined capsules having porous membranes and bulk supports |
US5578042A (en) | 1994-03-14 | 1996-11-26 | Cumming; J. Stuart | Ophthalmic kit and method for lens insertion |
US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
US5476448A (en) * | 1994-10-19 | 1995-12-19 | Urich; Alex | Apparatus for suppressing a vacuum surge in eye surgery |
AUPM897594A0 (en) | 1994-10-25 | 1994-11-17 | Daratech Pty Ltd | Controlled release container |
AU708529B2 (en) | 1994-11-10 | 1999-08-05 | University Of Kentucky Research Foundation, The | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5792099A (en) * | 1995-02-14 | 1998-08-11 | Decamp; Dennis | Syringe and cannula for insertion of viscoelastic material into an eye and method of using same |
US5554132A (en) | 1995-03-30 | 1996-09-10 | Abbott Laboratories | Hand grip for use with syringe |
US5674193A (en) | 1995-04-05 | 1997-10-07 | Hayes; Lili L. | Oral/nasal-gastric drainage kit |
IL113723A (en) | 1995-05-14 | 2002-11-10 | Optonol Ltd | Intraocular implant |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US6641708B1 (en) | 1996-01-31 | 2003-11-04 | Board Of Regents, The University Of Texas System | Method and apparatus for fractionation using conventional dielectrophoresis and field flow fractionation |
GB2310149A (en) | 1996-02-15 | 1997-08-20 | Nomix Chipman Ltd | Spray gun |
US20090005864A1 (en) | 1996-03-18 | 2009-01-01 | Eggleston Harry C | Modular intraocular implant |
US5951512A (en) | 1996-05-28 | 1999-09-14 | Horizon Medical Products, Inc. | Infusion port with modified drug reservoir |
US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US5928662A (en) | 1996-07-31 | 1999-07-27 | Phillips; Andrew F. | Ocular drug delivery device |
US6544193B2 (en) | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
AU7533696A (en) | 1996-12-13 | 1998-06-18 | Ciba-Geigy Ag | New materials |
US5755684A (en) | 1996-12-20 | 1998-05-26 | Chen; Jen-Yie | Volume homeostatic fluid-fluid exchanger |
DE69816980T2 (de) | 1997-03-31 | 2004-07-22 | Alza Corp., Palo Alto | Implantierbares diffusionabgabesystem |
US7160687B1 (en) | 1997-05-29 | 2007-01-09 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US5968008A (en) | 1997-08-04 | 1999-10-19 | Grams; Guenter A. | Cannula with parallel channels and sliding sheath |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6331523B1 (en) | 1998-03-12 | 2001-12-18 | Genentech, Inc. | Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5 |
US6196993B1 (en) | 1998-04-20 | 2001-03-06 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
US6695821B1 (en) * | 1998-06-17 | 2004-02-24 | Raymond N. Sjaarda | Surgical infusion tool with flow diffuser |
FR2784296B1 (fr) | 1998-09-18 | 2001-01-05 | Imedex Biomateriaux | Dispositif pour la formulation et la delivrance d'un melange, notamment pour l'application chirurgicale de ce melange |
US7973068B2 (en) | 1998-10-20 | 2011-07-05 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
ATE267032T1 (de) | 1998-12-14 | 2004-06-15 | Tre Esse Progettazione Biomedi | Kathetersystem zur durchführung einer intramyokardialen therapeutischen behandlung |
DE19948783C2 (de) | 1999-02-18 | 2001-06-13 | Alcove Surfaces Gmbh | Implantat |
US7914442B1 (en) | 1999-03-01 | 2011-03-29 | Gazdzinski Robert F | Endoscopic smart probe and method |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6472162B1 (en) | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
ES2213001T3 (es) | 1999-06-18 | 2004-08-16 | Alcon Manufacturing Ltd. | Metodo para seleccionar la concentracion de un farmaco antihistaminico anfipatico mediante determinacion del valor de actividad superficial del farmaco. |
US6551291B1 (en) | 1999-08-04 | 2003-04-22 | Johns Hopkins University | Non-traumatic infusion cannula and treatment methods using same |
US6638263B1 (en) | 1999-10-12 | 2003-10-28 | Durect Corporation | Regulation of drug delivery through flow diversion |
US6468264B1 (en) * | 1999-10-12 | 2002-10-22 | Durect Corporation | Closed exchange system |
US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
MXPA02002338A (es) | 1999-10-21 | 2002-07-30 | Alcon Universal Ltd | Dispositivo para la entrega de drogas. |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US20050119737A1 (en) | 2000-01-12 | 2005-06-02 | Bene Eric A. | Ocular implant and methods for making and using same |
US20030212383A1 (en) | 2001-01-05 | 2003-11-13 | Dana Cote | System and methods for reducing intraocular pressure |
CA2397166A1 (en) | 2000-01-12 | 2001-07-19 | Becton, Dickinson And Company | Systems and methods for reducing intraocular pressure |
DE10008826C2 (de) * | 2000-02-25 | 2002-03-14 | Disetronic Licensing Ag | Mikroperfusionsvorrichtung mit Sammelbehältnis |
US7077848B1 (en) | 2000-03-11 | 2006-07-18 | John Hopkins University | Sutureless occular surgical methods and instruments for use in such methods |
US7169444B2 (en) | 2000-03-13 | 2007-01-30 | Seiko Epson Corporation | Method for treating surface of ink jet recording medium having recorded image |
US7141152B2 (en) | 2000-03-16 | 2006-11-28 | Le Febre David A | Analyte species separation system |
US20050049578A1 (en) | 2000-04-14 | 2005-03-03 | Hosheng Tu | Implantable ocular pump to reduce intraocular pressure |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US20040208910A1 (en) | 2000-04-26 | 2004-10-21 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of adrenergic agents |
CA2420038C (en) | 2000-08-30 | 2010-11-09 | John Hopkins University | Devices for intraocular drug delivery |
ES2294025T3 (es) | 2000-09-06 | 2008-04-01 | Alcon, Inc. | Composiciones de revestimiento de pegajosidad cambiable para implantes oftalmicos. |
US6303290B1 (en) | 2000-09-13 | 2001-10-16 | The Trustees Of The University Of Pennsylvania | Encapsulation of biomaterials in porous glass-like matrices prepared via an aqueous colloidal sol-gel process |
US6869412B2 (en) * | 2000-11-13 | 2005-03-22 | Edward Allan Ross | Method and device for intravascular plasma fluid removal |
EP1345588A2 (en) | 2000-12-29 | 2003-09-24 | Bausch & Lomb Incorporated | Sustained release drug delivery devices |
WO2002053130A2 (en) | 2001-01-03 | 2002-07-11 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with coated drug cores |
JP2004521882A (ja) | 2001-01-03 | 2004-07-22 | ボシュ・アンド・ロム・インコーポレイテッド | 組立式透過性プラグを備えた徐放薬剤送達装置 |
WO2002053128A2 (en) | 2001-01-03 | 2002-07-11 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with multiple agents |
EP1372602B1 (en) | 2001-01-09 | 2007-04-18 | Microchips, Inc. | Flexible microchip devices for ophthalmic and other applications |
US6872198B1 (en) | 2001-01-24 | 2005-03-29 | Arrow International, Inc. | Double-y-shaped multi-lumen catheter with selectively attachable hubs |
EP1365738A2 (en) | 2001-01-26 | 2003-12-03 | Bausch & Lomb Incorporated | Improved process for the production of sustained release drug delivery devices |
US7181287B2 (en) | 2001-02-13 | 2007-02-20 | Second Sight Medical Products, Inc. | Implantable drug delivery device |
FR2821672B1 (fr) * | 2001-03-02 | 2003-05-02 | Scp Dosagene R & D | Moyens pour l'extraction de produits a analyser et leurs applications en diagnostic et analyse |
US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US6533769B2 (en) | 2001-05-03 | 2003-03-18 | Holmen Joergen | Method for use in cataract surgery |
GB2375964B (en) * | 2001-05-31 | 2003-12-24 | Intermark Medical Innovations | A device for colonic lavage |
EP1404297B1 (en) | 2001-06-12 | 2011-04-27 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
CA2448558A1 (en) | 2001-07-10 | 2003-01-23 | Teva Pharmaceutical Industries, Ltd. | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
IL144446A0 (en) | 2001-07-19 | 2002-05-23 | Prochon Biotech Ltd | Plasma protein matrices and methods for their preparation |
JP4261343B2 (ja) | 2001-07-23 | 2009-04-30 | アルコン,インコーポレイティド | 眼薬投与装置 |
WO2003009784A1 (en) | 2001-07-23 | 2003-02-06 | Alcon, Inc. | Ophthalmic drug delivery device |
US7749528B2 (en) | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
ES2393101T3 (es) | 2001-08-29 | 2012-12-18 | Ricardo A. P. De Carvalho | Sistema implantable y sellable para la administración unidireccional de agentes terapéuticos a tejidos diana |
WO2003028765A1 (fr) | 2001-09-28 | 2003-04-10 | Santen Pharmaceutical Co., Ltd. | Injections pour tissu oculaire contenant un medicament lie a du polyethylene glycol |
AU2002341959A1 (en) | 2001-10-04 | 2003-04-14 | Case Western Reserve University | Drug delivery devices and methods |
US8663687B2 (en) | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
AU2002352746A1 (en) | 2001-11-15 | 2003-06-10 | Arryx, Inc. | Sample chip |
US20030120217A1 (en) * | 2001-12-21 | 2003-06-26 | Abergel R. Patrick | Methods and devices for sclerotherapy |
GB2399753B (en) | 2002-01-18 | 2006-04-19 | Michael E Snyder | Method of making a sustained release ophthalmological device |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7186232B1 (en) | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
RU2322233C2 (ru) | 2002-03-11 | 2008-04-20 | Алькон, Инк. | Имплантируемая система для доставки лекарственных средств |
US7074426B2 (en) | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US6936033B2 (en) * | 2002-06-14 | 2005-08-30 | Medtronic, Inc. | Multiple ratio fluid dispenser |
US7939094B2 (en) | 2002-06-19 | 2011-05-10 | Boston Scientific Scimed, Inc. | Multiphase polymeric drug release region |
DK1521572T3 (da) | 2002-07-15 | 2009-05-04 | Alcon Inc | Biologisk nedbrydelig film til indförsel af öjenlægemiddel |
US8425549B2 (en) | 2002-07-23 | 2013-04-23 | Reverse Medical Corporation | Systems and methods for removing obstructive matter from body lumens and treating vascular defects |
US20040019325A1 (en) | 2002-07-29 | 2004-01-29 | Medrip Ltd. | Syringe Pump |
US20070219632A1 (en) | 2002-08-02 | 2007-09-20 | David Castillejos | Method and intra-sclera implant for treatment of glaucoma and presbyopia |
US7468065B2 (en) | 2002-09-18 | 2008-12-23 | Allergan, Inc. | Apparatus for delivery of ocular implants |
TWI282271B (en) | 2002-09-18 | 2007-06-11 | Allergan Inc | Apparatus for delivery of ocular implants |
JP2006507368A (ja) | 2002-09-29 | 2006-03-02 | サーモディックス,インコーポレイティド | ステロイド含有治療剤の網膜下投与方法;脈絡膜及び網膜に薬力学作用を局在化するための方法;並びに網膜疾患の治療及び/又は予防のための関連する方法 |
US7794437B2 (en) | 2003-01-24 | 2010-09-14 | Doheny Retina Institute | Reservoirs with subretinal cannula for subretinal drug delivery |
WO2004073551A2 (en) | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
US20060258000A1 (en) | 2003-02-26 | 2006-11-16 | Allen Jared W | Use of steady-state oxygen gradients to modulate animal cell functions |
US20050074497A1 (en) | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
US7094222B1 (en) | 2003-04-28 | 2006-08-22 | The United States Of America As Represented By The Secretary Of Navy | Syringe device for simultaneous infusion and withdrawal |
EP1633320A2 (en) | 2003-05-02 | 2006-03-15 | SurModics, Inc. | Implantable controlled release bioactive agent delivery device |
EP1671624B1 (en) | 2003-05-02 | 2010-08-11 | SurModics, Inc. | Delivery device for a controlled drug release of an active agent into the posterior section of the eye |
EP1635876A4 (en) | 2003-06-13 | 2009-05-06 | Becton Dickinson Co | IMPROVED INTRADERMAL ADMINISTRATION OF BIOACTIVE AGENTS |
US20040260381A1 (en) | 2003-06-18 | 2004-12-23 | D-Crown Ltd | Devices and methods for forming stenting structures in situ |
US20040260380A1 (en) | 2003-06-18 | 2004-12-23 | D-Crown Ltd | Devices for delivering multiple stenting structures in situ |
WO2004112653A2 (en) | 2003-06-18 | 2004-12-29 | D-Crown Ltd. | Devices and methods for delivering and forming single and multiple stenting structures in situ |
US8367410B2 (en) | 2003-06-20 | 2013-02-05 | Massachusetts Institute Of Technology | Application of electrical stimulation for functional tissue engineering in vitro and in vivo |
MXPA05011517A (es) | 2003-07-10 | 2005-12-12 | Alcon Inc | Dispositivo para el suministro de medicamentos oftalmicos. |
US7391593B2 (en) | 2003-07-31 | 2008-06-24 | Inphase Technologies, Inc. | Cartridge shutter mechanism |
FI120333B (fi) | 2003-08-20 | 2009-09-30 | Bioretec Oy | Huokoinen lääketieteellinen väline ja menetelmä sen valmistamiseksi |
JP4603547B2 (ja) | 2003-09-11 | 2010-12-22 | セラノス, インコーポレイテッド | 検体の監視および薬物送達のための医療デバイス |
CA2539324A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
US20050181018A1 (en) * | 2003-09-19 | 2005-08-18 | Peyman Gholam A. | Ocular drug delivery |
EP1675636A4 (en) | 2003-09-24 | 2009-12-23 | Medi Stream Pty Ltd | MEDICATION HOLDER |
AU2006225241B2 (en) | 2003-09-24 | 2008-07-17 | Tianda Pharmaceuticals (Australia) Pty Limited | Medication Holder |
WO2005033798A2 (en) | 2003-10-03 | 2005-04-14 | University Of Washington | Electrochemical micromanufacturing system and method |
US7211272B2 (en) | 2003-12-22 | 2007-05-01 | Bausch & Lomb Incorporated | Drug delivery device |
US8523829B2 (en) | 2004-01-29 | 2013-09-03 | Becton, Dickinson And Company | Intravenous delivery system |
ATE488269T1 (de) | 2004-02-12 | 2010-12-15 | Neovista Inc | Gerät für die intraokulare brachytherapie |
US7276050B2 (en) | 2004-03-02 | 2007-10-02 | Alan Franklin | Trans-scleral drug delivery method and apparatus |
WO2005091922A2 (en) | 2004-03-03 | 2005-10-06 | Becton, Dickinson And Company | Methods and devices for improving delivery of a substance to skin |
US8591885B2 (en) | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20050256462A1 (en) | 2004-05-14 | 2005-11-17 | Underwood John R | Nozzle |
WO2006014484A2 (en) | 2004-07-02 | 2006-02-09 | Surmodics, Inc. | Methods and devices for the treatment of ocular conditions |
US7117870B2 (en) | 2004-07-26 | 2006-10-10 | Clarity Corporation | Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same |
US20060020253A1 (en) | 2004-07-26 | 2006-01-26 | Prescott Anthony D | Implantable device having reservoir with controlled release of medication and method of manufacturing the same |
JP2008509157A (ja) | 2004-08-06 | 2008-03-27 | ソフェリオン セラピューティクス,インコーポレイテッド | 抗血管新生ペプチドおよびその使用方法 |
WO2006031358A2 (en) | 2004-08-13 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses |
WO2006023530A2 (en) | 2004-08-16 | 2006-03-02 | Massachusetts Institute Of Technology | Compositions and methods for enhancing structural and functional nervous system reorganization and recovery |
WO2006031388A2 (en) | 2004-08-20 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dentritic polymers, crosslinked gels, and their uses in orthopedic applications |
US20060052754A1 (en) | 2004-09-04 | 2006-03-09 | Fields Douglas W | Thumb trigger syringe pole |
US7709049B2 (en) | 2004-09-10 | 2010-05-04 | Surmodics, Inc. | Methods, devices, and coatings for controlled active agent release |
MX366832B (es) | 2004-10-01 | 2019-07-24 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
EP1812030A4 (en) | 2004-10-14 | 2009-01-14 | Sopherion Therapeutics Inc | ANTI-ANGIOGENIC PEPTIDES AND METHODS OF USE THEREOF |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1817003B1 (en) | 2004-10-29 | 2018-02-21 | The Regents of The University of California | Porous silicon microparticles for drug delivery to the eye |
US20060129215A1 (en) | 2004-12-09 | 2006-06-15 | Helmus Michael N | Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery |
US20060154981A1 (en) | 2005-01-12 | 2006-07-13 | Alcon, Inc. | Method of reducing intraocular pressure and treating glaucoma |
EP1848541A4 (en) | 2005-02-07 | 2013-01-16 | Pharmalight Inc | METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
US20060233858A1 (en) | 2005-03-08 | 2006-10-19 | Allergan, Inc. | Systems and methods providing targeted intraocular drug delivery |
WO2006102378A2 (en) | 2005-03-21 | 2006-09-28 | Macusight, Inc. | Drug delivery systems for treatment of diseases or conditions |
US20070077270A1 (en) | 2005-03-28 | 2007-04-05 | Clemson University | Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear |
US20070066138A1 (en) | 2005-04-05 | 2007-03-22 | The Ohio State University Research Foundation | Diffusion Delivery Systems and Methods of Fabrication |
US20100168535A1 (en) | 2006-04-12 | 2010-07-01 | Mark Ries Robinson | Methods and apparatuses related to blood analyte measurement system |
US20060258994A1 (en) | 2005-05-12 | 2006-11-16 | Avery Robert L | Implantable delivery device for administering pharmacological agents to an internal portion of a body |
WO2006127962A2 (en) | 2005-05-25 | 2006-11-30 | Becton, Dickinson And Comapny | Particulate formulations for intradermal delivery of biologically active agents |
CA2612508A1 (en) | 2005-06-17 | 2006-12-28 | Dynamis Therapeutics, Inc. | Treatment of inflammatory conditions |
US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
GB0515140D0 (en) * | 2005-07-22 | 2005-08-31 | Ark Therapeutics Ltd | Therapeutic device |
US8663673B2 (en) | 2005-07-29 | 2014-03-04 | Surmodics, Inc. | Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility |
KR101045149B1 (ko) | 2005-08-04 | 2011-06-30 | 가부시키가이샤 가네카 | 금속 피복 폴리이미드 필름 |
EP1912574A4 (en) | 2005-08-10 | 2010-08-04 | Insight Instr Inc | TOOL FOR EXTRACTION OF GLASS BODY SAMPLES FROM AN EYE |
US20070212397A1 (en) | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
JP2009508593A (ja) | 2005-09-16 | 2009-03-05 | (オーエスアイ)アイテツク・インコーポレーテツド | 眼科用シリンジ |
US20080167600A1 (en) | 2005-09-26 | 2008-07-10 | Peyman Gholam A | Device for delivery of an agent to the eye and other sites |
US20080003219A1 (en) | 2005-09-26 | 2008-01-03 | Minu, L.L.C. | Delivery of an ocular agent |
US20070072933A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an ocular agent |
WO2007038453A2 (en) | 2005-09-26 | 2007-04-05 | Advanced Ocular Systems Limited | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation |
US20070071756A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
US20070083155A1 (en) * | 2005-09-27 | 2007-04-12 | Mile Creek Capital, Llc | Multi-lumen injection apparatus |
TW200732347A (en) | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
EP1948112A4 (en) | 2005-10-11 | 2011-04-13 | Podaima Blake | SMART MEDICAL COMPLIANCE PROCESS AND SYSTEM |
US20070197491A1 (en) | 2005-10-14 | 2007-08-23 | Alcon, Inc. | Method for treating primary and secondary forms of glaucoma |
US20080125406A1 (en) | 2005-10-14 | 2008-05-29 | Robin Alan L | Method for Treating Primary and Secondary Forms of Glaucoma |
PT1968594E (pt) | 2005-11-29 | 2010-11-18 | Glaxosmithkline Llc | Tratamento de distúrbios neovasculares oculares tais como degeneração macular, estrias angióides, uveite e edema macular |
JP4721425B2 (ja) | 2005-12-01 | 2011-07-13 | キヤノン株式会社 | 流体移動方法および流体移動装置 |
US9446226B2 (en) | 2005-12-07 | 2016-09-20 | Ramot At Tel-Aviv University Ltd. | Drug-delivering composite structures |
KR20070060630A (ko) * | 2005-12-09 | 2007-06-13 | 한국전자통신연구원 | 위성추적 안테나 시스템 |
US20070131610A1 (en) | 2005-12-13 | 2007-06-14 | General Electric Company | Membrane-based apparatus and associated method |
US20070131611A1 (en) | 2005-12-13 | 2007-06-14 | General Electric Company | Membrane-based article and associated method |
PT2526910E (pt) | 2006-01-17 | 2015-11-18 | Transcend Medical Inc | Dispositivo para tratamento de glaucoma |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
US20080216736A1 (en) | 2006-01-19 | 2008-09-11 | Takeda San Diego, Inc. | Microfluidic device with diffusion between adjacent lumens |
US8979770B2 (en) | 2006-02-24 | 2015-03-17 | Merck Sharp & Dohme Corp. | Extraction and diagnostic fluid devices, systems and methods of use |
WO2007101204A1 (en) | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
US20070212387A1 (en) | 2006-03-08 | 2007-09-13 | Sahajanand Medical Technologies Pvt. Ltd. | Coatings for implantable medical devices |
WO2007117394A2 (en) | 2006-03-31 | 2007-10-18 | Dynamis Therapeutics, Inc. | Compositions and methods related to fructosamine-3-kinase inhibitors |
CN101505681B (zh) * | 2006-03-31 | 2013-09-04 | Qlt有限公司 | 用于药物治疗的鼻泪引流系统植入物 |
BRPI0709672B8 (pt) * | 2006-03-31 | 2021-06-22 | 3088922 Inc | implante ocular insersível em um lúmen ocular e método de distribuição de um agente terapêutico a um olho |
US7547300B2 (en) | 2006-04-12 | 2009-06-16 | Icu Medical, Inc. | Vial adaptor for regulating pressure |
WO2007118372A1 (fr) | 2006-04-18 | 2007-10-25 | Zhongshan Botai Pharmaceutic Instruments Co., Ltd. | Seringue stérilisée servant au mélange de médicaments |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
WO2007131050A2 (en) | 2006-05-02 | 2007-11-15 | Georgia Tech Research Corporation | Method for drug delivery to ocular tissue using microneedle |
US7981096B2 (en) | 2006-05-12 | 2011-07-19 | David Castillejos | Optic nerve head implant and medication delivery system |
US20070270750A1 (en) * | 2006-05-17 | 2007-11-22 | Alcon, Inc. | Drug delivery device |
US20080124372A1 (en) | 2006-06-06 | 2008-05-29 | Hossainy Syed F A | Morphology profiles for control of agent release rates from polymer matrices |
US8968782B2 (en) | 2006-06-28 | 2015-03-03 | Surmodics, Inc. | Combination degradable and non-degradable matrices for active agent delivery |
TW200815045A (en) | 2006-06-29 | 2008-04-01 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of ropinirole and methods of use thereof |
US20080019265A1 (en) | 2006-07-18 | 2008-01-24 | Paul Alluisi | Systems and methods for configuring a network to include redundant upstream connections using an upstream control protocol |
US8104331B2 (en) | 2006-07-19 | 2012-01-31 | Noab Biodiscoveries Inc. | Method and device to extract components contained in a fluid |
CA2657380A1 (en) | 2006-07-20 | 2008-01-24 | Neurosystec Corporation | Devices, systems and methods for ophthalmic drug delivery |
ATE469077T1 (de) | 2006-07-27 | 2010-06-15 | Indag Gmbh | Vorrichtung und verfahren zum aufteilen eines stroms von gegenständen |
WO2008016712A2 (en) | 2006-08-02 | 2008-02-07 | Inframat Corporation | Medical devices and methods of making and using |
US9039761B2 (en) * | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
JP2008054521A (ja) | 2006-08-29 | 2008-03-13 | Canon Inc | 細胞培養処理装置及び細胞培養処理方法 |
WO2008033924A2 (en) | 2006-09-12 | 2008-03-20 | Board Of Regents Of The University Of Nebraska | Methods and compositions for targeted delivery of therapeutic agents |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US20080089923A1 (en) | 2006-09-29 | 2008-04-17 | Burkstrand Michael J | Biodegradable ocular implants and methods for treating ocular conditions |
TW200817039A (en) | 2006-10-06 | 2008-04-16 | Dynamis Therapeutics Inc | Compositions and methods for skin lightening |
US9022970B2 (en) | 2006-10-16 | 2015-05-05 | Alcon Research, Ltd. | Ophthalmic injection device including dosage control device |
US8609148B2 (en) | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
EP2097107B1 (en) | 2006-10-25 | 2016-05-04 | Revalesio Corporation | Therapeutic treatment of eyes using an oxygen-enriched solution |
EP2083876A4 (en) | 2006-10-25 | 2012-09-19 | Revalesio Corp | WOUND CARE AND TREATMENT METHOD |
US20080108954A1 (en) | 2006-11-02 | 2008-05-08 | Jean-Marie Mathias | Flow Controllers |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US20080111282A1 (en) | 2006-11-10 | 2008-05-15 | Baojun Xie | Process for Making Three Dimensional Objects From Dispersions of Polymer Colloidal Particles |
US20100286791A1 (en) | 2006-11-21 | 2010-11-11 | Goldsmith David S | Integrated system for the ballistic and nonballistic infixion and retrieval of implants |
WO2008070118A1 (en) | 2006-12-05 | 2008-06-12 | Landec Corporation | Drug delivery |
US20090263346A1 (en) | 2006-12-05 | 2009-10-22 | David Taft | Systems and methods for delivery of drugs |
US20080154241A1 (en) | 2006-12-07 | 2008-06-26 | Burkstrand Michael J | Latent stabilization of bioactive agents releasable from implantable medical articles |
US20080147021A1 (en) | 2006-12-15 | 2008-06-19 | Jani Dharmendra M | Drug delivery devices |
DE202006018986U1 (de) * | 2006-12-16 | 2008-04-17 | Human Med Ag | Applikator für eine Wasserstrahleinrichtung, insbesondere zur Behandlung von Wunden und Geschwüren |
ZA200903649B (en) | 2006-12-18 | 2010-08-25 | Alcon Res Ltd | Devices and methods for ophthalmic drug delivery |
CA2674076A1 (en) | 2006-12-26 | 2008-07-10 | Qlt Plug Delivery, Inc. | Drug delivery implants for inhibition of optical defects |
EP2124857B1 (en) | 2007-01-09 | 2017-03-29 | Fovea Pharmaceuticals | Apparatus for intra-ocular injection |
AU2008206953A1 (en) | 2007-01-19 | 2008-07-24 | Cinvention Ag | Porous, non-degradable implant made by powder molding |
UY30883A1 (es) | 2007-01-31 | 2008-05-31 | Alcon Res | Tapones punctales y metodos de liberacion de agentes terapeuticos |
GB0702864D0 (en) | 2007-02-14 | 2007-03-28 | Benoist Girard Sas | Prosthetic implant for use without bone cement |
WO2008116165A2 (en) | 2007-03-21 | 2008-09-25 | Next Safety, Inc. | Methods and systems of delivering medication via inhalation |
JP2010522060A (ja) | 2007-03-23 | 2010-07-01 | アレジアンス、コーポレイション | 交換可能な収集および他の機能を有する流体収集および廃棄システムならびに関連する方法 |
US7642978B2 (en) * | 2007-03-30 | 2010-01-05 | Itt Manufacturing Enterprises, Inc. | Method and apparatus for steering and stabilizing radio frequency beams utilizing photonic crystal structures |
US20080249501A1 (en) | 2007-04-09 | 2008-10-09 | Medtronic Vascular, Inc. | Methods for Simultaneous Injection and Aspiration of Fluids During a Medical Procedure |
RU2009144142A (ru) | 2007-04-30 | 2011-06-10 | Алькон Рисерч, Лтд. (Us) | Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента |
US20080286338A1 (en) | 2007-05-15 | 2008-11-20 | Boston Foundation For Sight | Drug delivery system with scleral lens |
US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
EP2164866B1 (en) | 2007-05-29 | 2014-05-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US20090009416A1 (en) * | 2007-07-02 | 2009-01-08 | Viasat, Inc. | Full-motion multi-antenna multi-functional pedestal |
KR101138894B1 (ko) | 2007-07-30 | 2012-05-14 | 가부시끼가이샤 제이엠에스 | 혈액성분 분리수용장치 |
US20090036827A1 (en) | 2007-07-31 | 2009-02-05 | Karl Cazzini | Juxtascleral Drug Delivery and Ocular Implant System |
US9808557B2 (en) | 2007-08-10 | 2017-11-07 | Trustees Of Tufts College | Tubular silk compositions and methods of use thereof |
US7901726B2 (en) | 2007-08-31 | 2011-03-08 | Boston Scientific Scimed, Inc. | Porous medical articles for therapeutic agent delivery |
KR20100058620A (ko) | 2007-09-07 | 2010-06-03 | 큐엘티 플러그 딜리버리, 인코포레이티드 | 눈물 임플랜트용 삽입 및 적출 기구 |
DK2207529T3 (en) | 2007-09-07 | 2015-03-09 | Mati Therapeutics Inc | PHARMACEUTICAL cores for the sustained release of therapeutic agents |
AU2008300022A1 (en) | 2007-09-07 | 2009-03-19 | Qlt Inc. | Lacrimal implant detection |
CN104856782B (zh) | 2007-09-07 | 2017-09-12 | 马缇医疗股份有限公司 | 泪腺植入物及相关方法 |
US7777480B2 (en) * | 2007-09-08 | 2010-08-17 | Andrew Llc | Antenna Orientation Sensor |
US20090081272A1 (en) | 2007-09-24 | 2009-03-26 | John Clarke | Medical devices having a metal particulate composition for controlled diffusion |
US8308755B2 (en) | 2007-09-24 | 2012-11-13 | Ethicon Endo-Surgery, Inc. | Elliptical retractor |
US8974809B2 (en) | 2007-09-24 | 2015-03-10 | Boston Scientific Scimed, Inc. | Medical devices having a filter insert for controlled diffusion |
US20090214601A1 (en) | 2007-09-28 | 2009-08-27 | Chappa Ralph A | Porous Drug Delivery Devices and Related Methods |
US20100100043A1 (en) | 2007-10-05 | 2010-04-22 | Racenet Danyel J | Flexible Access Device For Use In Surgical Procedure |
KR101511497B1 (ko) | 2007-10-05 | 2015-04-13 | 코비디엔 엘피 | 수술 절차에 사용하기 위한 밀봉부 고정구 |
US20100009008A1 (en) | 2007-10-25 | 2010-01-14 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
US20100008997A1 (en) | 2007-10-25 | 2010-01-14 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
US20100310665A1 (en) | 2007-10-25 | 2010-12-09 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
US20090263495A1 (en) | 2007-10-25 | 2009-10-22 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
US20100303918A1 (en) | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
US20100303917A1 (en) | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for treating cystic fibrosis |
US20090227018A1 (en) | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
WO2010062628A1 (en) | 2008-10-27 | 2010-06-03 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
US20100004189A1 (en) | 2007-10-25 | 2010-01-07 | Revalesio Corporation | Compositions and methods for treating cystic fibrosis |
CN101909869B (zh) | 2007-10-25 | 2014-12-17 | 利发利希奥公司 | 抑菌或杀菌的组合物和方法 |
MX2010004366A (es) | 2007-11-05 | 2010-05-05 | Bausch & Lomb | Materiales inmiscibles en agua como vehiculos para suministro de farmacos. |
US8545457B2 (en) * | 2007-11-08 | 2013-10-01 | Terumo Kabushiki Kaisha | Sprayer |
US8114883B2 (en) | 2007-12-04 | 2012-02-14 | Landec Corporation | Polymer formulations for delivery of bioactive materials |
ES2425769T5 (es) | 2007-12-20 | 2017-07-28 | University Of Southern California | Aparato para la administración de agentes terapéuticos |
US8414646B2 (en) | 2007-12-27 | 2013-04-09 | Forsight Labs, Llc | Intraocular, accommodating lens and methods of use |
US20100305514A1 (en) | 2008-01-10 | 2010-12-02 | Bausch & Lomb Incorporated | Intravitreal injection system having coaxial cannulae and use thereof |
WO2009094466A2 (en) | 2008-01-22 | 2009-07-30 | University Of Florida Research Foundation, Inc. | Contact lenses for extended release of bioactive agents containing diffusion attenuators |
JP2011510750A (ja) | 2008-01-29 | 2011-04-07 | クライマン、ギルバート・エイチ | 薬物送達デバイス、キット及びそれらの方法 |
US8201752B2 (en) | 2008-03-10 | 2012-06-19 | Vapore, Inc. | Low energy vaporization of liquids: apparatus and methods |
TNSN08110A1 (en) | 2008-03-11 | 2009-07-14 | Rekik Raouf Dr | Drug delivery to the anterior and posterior segment of the eye from drops |
US20090240208A1 (en) | 2008-03-19 | 2009-09-24 | Warsaw Orthopedic, Inc. | Microparticle delivery syringe and needle for placing particle suspensions and removing vehicle fluid |
WO2009117112A2 (en) | 2008-03-21 | 2009-09-24 | Novartis Ag | Powder dispersion apparatus, method of making and using the apparatus, components that can be used on the apparatus and other devices, and various active agents |
KR101674492B1 (ko) | 2008-03-31 | 2016-11-09 | 닛토덴코 가부시키가이샤 | 침투제 전달 시스템 및 그의 사용방법 |
SI2285439T1 (sl) | 2008-04-04 | 2014-05-30 | Nektar Therapeutics | Naprava za aerosolizacijo |
US8801665B2 (en) | 2008-04-10 | 2014-08-12 | Henry Ford Health System | Apparatus and method for controlled depth of injection into myocardial tissue |
EP2276508A4 (en) | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | RELEASE OF LFA-1 ANTAGONISTS AGAINST THE GAS-DARM SYSTEM |
CN104623741A (zh) | 2008-04-30 | 2015-05-20 | 马缇医疗股份有限公司 | 复合泪管植入物及相关方法 |
CA2723215A1 (en) | 2008-05-01 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
EP2320989B1 (en) | 2008-05-08 | 2015-03-11 | MiniPumps, LLC | Implantable pumps and cannulas therefor |
WO2009158144A1 (en) | 2008-05-30 | 2009-12-30 | Fairfield Clinical Trials Llc | Method and composition for dermatoses |
US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
CA2769307C (en) | 2008-07-11 | 2017-12-12 | Intellicyt Corporation | Multi-sample particle analyzer system and method for high throughput screening |
US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
CN102159126A (zh) | 2008-07-21 | 2011-08-17 | 阿尔斯塔西斯公司 | 在组织中形成管道的装置、方法和成套用具 |
US20100022943A1 (en) | 2008-07-25 | 2010-01-28 | Medtronic Vascular, Inc. | Hydrodynamic Thrombectomy Catheter |
US20100023033A1 (en) | 2008-07-25 | 2010-01-28 | Medtronic Vescular, Inc. | Hydrodynamic Thrombectomy Catheter |
US7699820B1 (en) * | 2008-08-12 | 2010-04-20 | French Ronald J | Device for irrigating the ear canal |
WO2010021993A1 (en) | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
US8221353B2 (en) | 2008-10-21 | 2012-07-17 | KMG Pharma, Inc | Intravitreal injection device and system |
US7678078B1 (en) | 2008-10-21 | 2010-03-16 | KMG Pharma LLC | Intravitreal injection device, system and method |
WO2010062394A2 (en) | 2008-11-26 | 2010-06-03 | Surmodics, Inc. | Implantable ocular drug delivery device and methods |
DE102008054431B3 (de) | 2008-12-09 | 2010-06-17 | Pari Pharma Gmbh | Aerosoltherapievorrichtung |
US20100158980A1 (en) | 2008-12-18 | 2010-06-24 | Casey Kopczynski | Drug delivery devices for delivery of therapeutic agents |
US8545554B2 (en) | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
US8425473B2 (en) | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
PL2391419T3 (pl) | 2009-01-29 | 2019-12-31 | Forsight Vision4, Inc. | Dostarczanie leku do tylnego odcinka |
US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
PT2398500T (pt) | 2009-02-20 | 2019-06-14 | 2 Bbb Medicines B V | Sistema de entrega de medicamentos à base de glutationas |
US8912236B2 (en) | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
US8424367B2 (en) | 2009-03-04 | 2013-04-23 | University Of South Carolina | Systems and methods for measurement of gas permeation through polymer films |
MX2011011333A (es) | 2009-04-27 | 2011-11-18 | Revalesio Corp | Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. |
WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
CN102802541A (zh) | 2009-05-15 | 2012-11-28 | 阿尔斯塔西斯公司 | 在组织中形成管道的装置、方法和成套用具 |
CA2979355C (en) | 2009-05-18 | 2023-02-21 | Dose Medical Corporation | Drug eluting ocular implant |
ES2921527T3 (es) | 2009-06-03 | 2022-08-29 | Forsight Vision5 Inc | Administración de fármaco en segmento anterior |
US20120130300A1 (en) | 2009-07-14 | 2012-05-24 | Board Of Regents, The Univerity Of Texas System | Therapeutic Methods Using Controlled Delivery Devices Having Zero Order Kinetics |
US20110033933A1 (en) | 2009-07-15 | 2011-02-10 | Morteza Gharib | Method applying hemodynamic forcing and klf2 to initiate the growth and development of cardiac valves |
MX2012001716A (es) | 2009-08-14 | 2012-04-02 | Genentech Inc | Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf. |
EP2473160A4 (en) | 2009-09-01 | 2015-06-03 | Univ Northwestern | ADMINISTRATION OF THERAPEUTIC AGENTS WITH OLIGONUCLEOTIDE-MODIFIED NANOPARTICLES AS SUPPORT |
EP2480270A4 (en) | 2009-09-21 | 2015-07-08 | Harvard Apparatus Regenerative Technology Inc | METHODS AND APPARATUSES FOR INTRODUCING CELLS INTO A TISSUE SITE |
EP2515864A4 (en) | 2009-12-23 | 2013-09-11 | Psivida Inc | DELAYED RELEASE DELIVERY DEVICES |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US8821474B2 (en) | 2010-02-22 | 2014-09-02 | Microsert Ltd. | Slow release liquid drug delivery device |
US8038650B2 (en) | 2010-02-22 | 2011-10-18 | Microsert Ltd. | Slow release liquid drug delivery device |
AR081364A1 (es) | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
AU2011285637B2 (en) | 2010-08-05 | 2014-10-30 | Forsight Vision4, Inc. | Subconjunctival implant for posterior segment drug delivery |
WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
SI2600812T1 (sl) | 2010-08-05 | 2021-12-31 | ForSight Vision4, Inc., | Naprava za zdravljenje očesa |
WO2012019136A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Injector apparatus and method for drug delivery |
WO2012065006A2 (en) | 2010-11-11 | 2012-05-18 | Forsight Vision4, Inc. | Methods and apparatus to determine porous structures for drug delivery |
US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
WO2012158773A2 (en) | 2011-05-16 | 2012-11-22 | Ico, Inc. | Filling and implanting accommodative intraocular lenses |
US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
RS61758B1 (sr) | 2011-09-16 | 2021-05-31 | Forsight Vision4 Inc | Aparati za razmenu tečnosti |
US20130150777A1 (en) | 2011-12-12 | 2013-06-13 | Sebastian Böhm | Glaucoma Drainage Devices Including Vario-Stable Valves and Associated Systems and Methods |
WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US9421129B2 (en) | 2012-04-02 | 2016-08-23 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
CA2905496A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
CN105246438B (zh) | 2013-03-28 | 2018-01-26 | 弗赛特影像4股份有限公司 | 用于输送治疗物质的眼科植入物 |
-
2011
- 2011-08-05 WO PCT/US2011/046812 patent/WO2012019136A2/en active Application Filing
- 2011-08-05 CN CN201510882273.8A patent/CN105435338B/zh active Active
- 2011-08-05 PL PL11815388T patent/PL2600930T3/pl unknown
- 2011-08-05 AU AU2011285545A patent/AU2011285545B2/en active Active
- 2011-08-05 DK DK11815388.1T patent/DK2600930T3/da active
- 2011-08-05 SI SI201131971T patent/SI2600930T1/sl unknown
- 2011-08-05 CA CA2807535A patent/CA2807535C/en active Active
- 2011-08-05 RS RS20210345A patent/RS61601B1/sr unknown
- 2011-08-05 HU HUE11815388A patent/HUE054113T2/hu unknown
- 2011-08-05 SG SG2013008933A patent/SG187730A1/en unknown
- 2011-08-05 LT LTEP11815388.1T patent/LT2600930T/lt unknown
- 2011-08-05 CN CN201180048628.3A patent/CN103209733B/zh active Active
- 2011-08-05 EP EP11815388.1A patent/EP2600930B1/en active Active
- 2011-08-05 EP EP21151209.0A patent/EP3861969A1/en active Pending
- 2011-08-05 JP JP2013523370A patent/JP6063382B2/ja active Active
- 2011-08-05 US US13/814,461 patent/US9033911B2/en active Active
- 2011-08-05 ES ES11815388T patent/ES2888906T3/es active Active
- 2011-08-05 PT PT118153881T patent/PT2600930T/pt unknown
-
2013
- 2013-05-07 US US13/889,328 patent/US8905963B2/en active Active
-
2014
- 2014-06-13 AU AU2014203235A patent/AU2014203235B2/en active Active
-
2015
- 2015-05-15 US US14/713,505 patent/US9861521B2/en active Active
-
2016
- 2016-01-07 AU AU2016200097A patent/AU2016200097B2/en active Active
- 2016-12-16 JP JP2016244154A patent/JP6326124B2/ja active Active
-
2017
- 2017-12-13 US US15/840,965 patent/US10265215B2/en active Active
-
2019
- 2019-04-17 US US16/386,854 patent/US11786396B2/en active Active
-
2021
- 2021-04-13 HR HRP20210587TT patent/HRP20210587T1/hr unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2646042A (en) * | 1951-05-18 | 1953-07-21 | Hu Quang Hsi | Medical apparatus |
JPH08509636A (ja) * | 1993-04-30 | 1996-10-15 | アラーガン、インコーポレイテッド | 接着性粘弾性物質の除去の為の器具及び方法 |
WO2009089094A2 (en) * | 2008-01-03 | 2009-07-16 | University Of Southern California | Implantable drug-delivery devices, and apparatus and methods for refilling the devices |
JP2011509120A (ja) * | 2008-01-03 | 2011-03-24 | ユニバーシティ オブ サザン カリフォルニア | 埋め込み可能な薬物送達デバイス、及び当該デバイスを補充するための装置および方法 |
WO2009137777A2 (en) * | 2008-05-08 | 2009-11-12 | Replenish Pumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
JP2011519695A (ja) * | 2008-05-08 | 2011-07-14 | リプレニッシュ パンプス, エルエルシー | 植設可能な薬物送達デバイスおよびそのデバイスを充填する装置および方法 |
WO2010078063A1 (en) * | 2009-01-02 | 2010-07-08 | Alcon Research, Ltd. | In-situ refillable ophthalmic implant |
JP2012514493A (ja) * | 2009-01-02 | 2012-06-28 | アルコン リサーチ, リミテッド | その場で再充填可能な眼用移植物 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021094405A (ja) * | 2014-11-10 | 2021-06-24 | フォーサイト・ビジョン フォー・インコーポレーテッドForsight Vision4, Inc. | 拡張可能な薬物送達デバイスおよび使用方法 |
JP7203868B2 (ja) | 2014-11-10 | 2023-01-13 | フォーサイト・ビジョン フォー・インコーポレーテッド | 拡張可能な薬物送達デバイスおよび使用方法 |
JP2023024439A (ja) * | 2014-11-10 | 2023-02-16 | フォーサイト・ビジョン フォー・インコーポレーテッド | 拡張可能な薬物送達デバイスおよび使用方法 |
JP7465616B2 (ja) | 2014-11-10 | 2024-04-11 | フォーサイト・ビジョン フォー・インコーポレーテッド | 拡張可能な薬物送達デバイスおよび使用方法 |
JP2019510581A (ja) * | 2016-04-05 | 2019-04-18 | フォーサイト・ビジョン フォー・インコーポレーテッドForsight Vision4, Inc. | 移植可能な眼薬送達デバイス |
JP7009384B2 (ja) | 2016-04-05 | 2022-01-25 | フォーサイト・ビジョン フォー・インコーポレーテッド | 移植可能な眼薬送達デバイス |
JP2021504071A (ja) * | 2017-11-21 | 2021-02-15 | フォーサイト・ビジョン4・インコーポレーテッドForSight Vision4, Inc. | 膨張可能ポート送達システムのための流体交換装置及びその使用方法 |
JP7314155B2 (ja) | 2017-11-21 | 2023-07-25 | フォーサイト・ビジョン4・インコーポレーテッド | 膨張可能ポート送達システムのための流体交換装置及びその使用方法 |
JP2021522180A (ja) * | 2018-04-17 | 2021-08-30 | アウトルック セラピューティクス,インコーポレイティド | ベバシズマブの緩衝製剤を用いる疾患の治療方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6326124B2 (ja) | 薬剤送達のための注入用装置 | |
JP6263217B2 (ja) | 埋め込み型治療デバイス | |
US20230338282A1 (en) | Posterior segment drug delivery | |
JP6111194B2 (ja) | 組み合わせ薬物送達方法および装置 | |
US20150297402A1 (en) | Implantable Therapeutic Device | |
EP2739252A1 (en) | Small molecule delivery with implantable therapeutic device | |
WO2012019047A2 (en) | Subconjunctival implant for posterior segment drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130409 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130403 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140625 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140625 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140805 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140805 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150604 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150630 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150916 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151102 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160420 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160620 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161020 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6063382 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |